VistaGen Therapeutics (VTGN) 10-K 28 Jun 23 2023 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2023	Jun. 22, 2023	Sep. 30, 2022
Document Information [Line Items]
Entity Central Index Key	0001411685
Entity Registrant Name	VistaGen Therapeutics, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-37761
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	20-5093315
Entity Address, Address Line One	343 Allerton Avenue
Entity Address, City or Town	South San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94080
City Area Code	650
Local Phone Number	577-3600
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	VTGN
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 31,202,662
Entity Common Stock, Shares Outstanding		7,872,479
Auditor Name	WithumSmith+Brown, PC
Auditor Location	San Francisco, California
Auditor Firm ID	100

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Current assets:
Cash and cash equivalents	$ 16,637,600	$ 68,135,300
Prepaid expenses and other current assets	802,700	2,745,800
Deferred contract acquisition costs - current portion	67,100	116,900
Total current assets	17,507,400	70,998,000
Property and equipment, net	507,300	414,300
Right-of-use asset – operating lease	2,260,300	2,662,000
Deferred offering costs	495,700	321,800
Deferred contract acquisition costs - non-current portion	217,600	146,400
Security deposits	100,900	100,900
Total assets	21,089,200	74,643,400
Current liabilities:
Accounts payable	2,473,100	2,758,600
Accrued expenses	787,400	1,329,200
Deferred revenue - current portion	714,300	1,244,000
Operating lease obligation - current portion	485,600	433,300
Financing lease obligation - current portion	1,700	0
Total current liabilities	4,567,400	5,765,100
Non-current liabilities:
Deferred revenue - non-current portion	2,314,600	1,557,600
Operating lease obligation - non-current portion	2,119,800	2,605,400
Financing lease obligation - non-current portion	7,400	0
Total non-current liabilities	4,441,800	4,163,000
Total liabilities	9,009,200	9,928,100
Commitments and contingencies (Note 14)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2023 and March 31, 2022: no shares outstanding at March 31, 2023 and March 31, 2022	0	0
Common stock, $0.001 par value; 325,000,000 shares authorized at March 31, 2023 and March 31, 2022; 7,315,404 and 6,889,221 shares issued at March 31, 2023 and March 31, 2022, respectively	7,300	6,900
Additional paid-in capital	342,892,500	336,280,500
Treasury stock, at cost, 4,522 shares of common stock held at March 31, 2023 and March 31, 2022	(3,968,100)	(3,968,100)
Accumulated deficit	(326,851,700)	(267,604,000)
Total stockholders’ equity	12,080,000	64,715,300
Total liabilities and stockholders’ equity	21,089,200	74,643,400
Collaborative Arrangement [Member]
Current liabilities:
Note payable	$ 105,300	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Preferred Stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred Stock, Par or Stated Value (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, shares outstanding (in shares)	0	0
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized (in shares)	325,000,000	325,000,000
Common Stock, Shares Issued (in shares)	7,315,404	6,889,221
Treasury stock, shares (in shares)	4,522	4,522

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended								12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Revenue, derecognized									$ (227,300)
Sublicense revenue										$ 1,108,900
Operating expenses:
Research and development	$ 9,337,000	$ 6,854,000	$ 12,895,000	$ 15,291,000	$ 12,234,000	$ 7,779,000	$ 9,937,000	$ 5,458,000	44,377,100	35,407,800
General and administrative	3,078,000	3,092,000	3,702,000	4,792,000	4,498,000	3,118,000	3,221,000	2,643,000	14,663,600	13,480,000
Total operating expenses	12,415,000	9,946,000	16,597,000	20,083,000	16,732,000	10,897,000	13,158,000	8,101,000	59,040,700	48,887,800
Loss from operations	(12,239,000)	(9,766,000)	(17,490,000)	(19,773,000)	(16,693,000)	(10,539,000)	(12,800,000)	(7,747,000)	(59,268,000)	(47,778,900)
Other income, net:
Interest income, net	13,000	5,000	6,000	2,000	5,000	5,000	5,000	5,000	26,200	19,900
Loss before income taxes	(12,226,000)	(9,761,000)	(17,484,000)	(19,771,000)	(16,688,000)	(10,534,000)	(12,795,000)	(7,742,000)	(59,241,800)	(47,759,000)
Income taxes	(1,000)	0	0	(5,000)	0	0	0	(3,000)	(5,900)	(3,400)
Net loss and comprehensive loss	$ (12,227,000)	$ (9,761,000)	$ (17,484,000)	$ (19,776,000)	(16,688,000)	(10,534,000)	(12,795,000)	(7,745,000)	(59,247,700)	(47,762,400)
Accrued dividend on Series B Preferred stock					0	(208,000)	(375,000)	(362,000)	0	(945,100)
Net loss attributable to common stockholders					$ (16,688,000)	$ (10,742,000)	$ (13,170,000)	$ (8,107,000)	$ (59,247,700)	$ (48,707,500)
Basic and diluted net loss per common share (in dollars per share)	$ (1.71)	$ (1.42)	$ (2.54)	$ (2.87)	$ (2.42)	$ (1.59)	$ (2.04)	$ (1.28)	$ (8.51)	$ (7.38)
Weighted average shares used in computing basic and diluted net loss per common share (in shares)	7,163,799	6,894,603	6,893,708	6,886,557	6,884,403	6,744,289	6,440,928	6,330,805	6,958,749	6,599,287

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	3 Months Ended				12 Months Ended
	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (12,227,000)	$ (19,776,000)	$ (16,688,000)	$ (7,745,000)	$ (59,247,700)	$ (47,762,400)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization					129,500	153,500
Stock-based compensation					3,336,400	3,480,700
Expense related to acquisition of Pherin Pharmaceuticals, Inc. recorded as an asset acquisition					3,559,400	0
Warrant modification expense					77,400	0
Amortization of operating lease right-of-use asset					401,700	557,600
Expense related to write-off of deferred offering costs					0	232,000
Changes in operating assets and liabilities:
Prepaid expenses and other current assets					3,188,400	(1,870,100)
Security deposits					0	(53,100)
Operating lease liability					(433,300)	(677,000)
Accounts payable and accrued expenses					(932,800)	1,686,900
Net cash used in operating activities					(49,715,100)	(45,256,500)
Cash flows from investing activities:
Purchases of laboratory and other equipment					(212,000)	(200,400)
Cash used in acquisition of Pherin Pharmaceuticals, Inc. as an asset acquisition					(528,300)	0
Net cash used in investing activities					(740,300)	(200,400)
Cash flows from financing activities:
Net proceeds from issuance of common stock, including option exercises					104,400	139,900
Net proceeds from exercise of warrants, net of underlying share registration expenses					0	5,948,500
Repayment of financing lease obligations					(1,500)	(3,000)
Repayment of note payable					(1,034,400)	0
Net cash (used in) provided by financing activities					(1,042,300)	10,483,900
Net decrease in cash and cash equivalents					(51,497,700)	(34,973,000)
Cash and cash equivalents at beginning of year		$ 68,135,300		$ 103,108,300	68,135,300	103,108,300
Cash and cash equivalents at end of year	16,637,600		68,135,300		16,637,600	68,135,300
Supplemental disclosure of noncash activities:
Insurance premiums settled by issuing note payable					1,139,700	0
Acquisition of office equipment subject to financing lease					10,600	0
Fair value of common stock issued for acquisition of Pherin Pharmaceuticals, Inc.					3,076,500	0
Accrued dividends on Series B Preferred settled upon conversion by issuance of common stock					0	7,217,800
Series B Preferred Stock [Member]
Supplemental disclosure of noncash activities:
Accrued dividends on Series B Preferred	$ 0		$ 945,100		0	945,100
ATM Facility [Member]
Cash flows from financing activities:
Net proceeds (expenses) from sale of common stock under At the Market (ATM) facility, net of deferred offering costs					(173,900)	4,299,000
Equity Line [Member]
Cash flows from financing activities:
Net proceeds (expenses) from sale of common stock under At the Market (ATM) facility, net of deferred offering costs					63,100	99,500
License [Member]
Changes in operating assets and liabilities:
Deferred sublicense revenue, net of deferred contract acquisition costs					$ 205,900	$ (1,004,600)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	3 Months Ended				12 Months Ended
	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2023	Mar. 31, 2022
Conversion of Series D Preferred Stock Into Common Stock [Member] | Preferred Stock [Member] | Series A Preferred Stock [Member]
Statement [Line Items]
Conversion of stock (in shares)						0
Conversion of stock						$ 0
Conversion of Series D Preferred Stock Into Common Stock [Member] | Preferred Stock [Member] | Series B Preferred Stock [Member]
Statement [Line Items]
Conversion of stock (in shares)						0
Conversion of stock						$ 0
Conversion of Series D Preferred Stock Into Common Stock [Member] | Preferred Stock [Member] | Series C Preferred Stock [Member]
Statement [Line Items]
Conversion of stock (in shares)						0
Conversion of stock						$ 0
Conversion of Series D Preferred Stock Into Common Stock [Member] | Preferred Stock [Member] | Series D Preferred Stock [Member]
Statement [Line Items]
Conversion of stock (in shares)						(402,149)
Conversion of stock						$ (400)
Conversion of Series D Preferred Stock Into Common Stock [Member] | Common Stock [Member]
Statement [Line Items]
Conversion of stock (in shares)						308,314
Conversion of stock						$ 300
Conversion of Series D Preferred Stock Into Common Stock [Member] | Additional Paid-in Capital [Member]
Statement [Line Items]
Conversion of stock						100
Conversion of Series D Preferred Stock Into Common Stock [Member] | Treasury Stock, Common [Member]
Statement [Line Items]
Conversion of stock						0
Conversion of Series D Preferred Stock Into Common Stock [Member] | Retained Earnings [Member]
Statement [Line Items]
Conversion of stock						0
Conversion of Series D Preferred Stock Into Common Stock [Member]
Statement [Line Items]
Conversion of stock						$ 0
Conversion of Series A Preferred into Common Stock [Member] | Preferred Stock [Member] | Series A Preferred Stock [Member]
Statement [Line Items]
Conversion of stock (in shares)						(500,000)
Conversion of stock						$ (500)
Conversion of Series A Preferred into Common Stock [Member] | Preferred Stock [Member] | Series B Preferred Stock [Member]
Statement [Line Items]
Conversion of stock (in shares)						0
Conversion of stock						$ 0
Conversion of Series A Preferred into Common Stock [Member] | Preferred Stock [Member] | Series C Preferred Stock [Member]
Statement [Line Items]
Conversion of stock (in shares)						0
Conversion of stock						$ 0
Conversion of Series A Preferred into Common Stock [Member] | Preferred Stock [Member] | Series D Preferred Stock [Member]
Statement [Line Items]
Conversion of stock (in shares)						0
Conversion of stock						$ 0
Conversion of Series A Preferred into Common Stock [Member] | Common Stock [Member]
Statement [Line Items]
Conversion of stock (in shares)						25,000
Conversion of stock						$ 0
Conversion of Series A Preferred into Common Stock [Member] | Additional Paid-in Capital [Member]
Statement [Line Items]
Conversion of stock						500
Conversion of Series A Preferred into Common Stock [Member] | Treasury Stock, Common [Member]
Statement [Line Items]
Conversion of stock						0
Conversion of Series A Preferred into Common Stock [Member] | Retained Earnings [Member]
Statement [Line Items]
Conversion of stock						0
Conversion of Series A Preferred into Common Stock [Member]
Statement [Line Items]
Conversion of stock						$ 0
Conversion of Series B Preferred Stock Into Common Stock [Member] | Preferred Stock [Member] | Series A Preferred Stock [Member]
Statement [Line Items]
Conversion of stock (in shares)						0
Conversion of stock						$ 0
Conversion of Series B Preferred Stock Into Common Stock [Member] | Preferred Stock [Member] | Series B Preferred Stock [Member]
Statement [Line Items]
Conversion of stock (in shares)						(1,131,669)
Conversion of stock						$ (1,100)
Conversion of Series B Preferred Stock Into Common Stock [Member] | Preferred Stock [Member] | Series C Preferred Stock [Member]
Statement [Line Items]
Conversion of stock (in shares)						0
Conversion of stock						$ 0
Conversion of Series B Preferred Stock Into Common Stock [Member] | Preferred Stock [Member] | Series D Preferred Stock [Member]
Statement [Line Items]
Conversion of stock (in shares)						0
Conversion of stock						$ 0
Conversion of Series B Preferred Stock Into Common Stock [Member] | Common Stock [Member]
Statement [Line Items]
Conversion of stock (in shares)						147,582
Conversion of stock						$ 200
Conversion of Series B Preferred Stock Into Common Stock [Member] | Additional Paid-in Capital [Member]
Statement [Line Items]
Conversion of stock						7,218,700
Conversion of Series B Preferred Stock Into Common Stock [Member] | Treasury Stock, Common [Member]
Statement [Line Items]
Conversion of stock						0
Conversion of Series B Preferred Stock Into Common Stock [Member] | Retained Earnings [Member]
Statement [Line Items]
Conversion of stock						0
Conversion of Series B Preferred Stock Into Common Stock [Member]
Statement [Line Items]
Conversion of stock						$ 7,217,800
Conversion of Series C Preferred Stock to Common Stock [Member] | Preferred Stock [Member] | Series A Preferred Stock [Member]
Statement [Line Items]
Conversion of stock (in shares)						0
Conversion of stock						$ 0
Conversion of Series C Preferred Stock to Common Stock [Member] | Preferred Stock [Member] | Series B Preferred Stock [Member]
Statement [Line Items]
Conversion of stock (in shares)						0
Conversion of stock						$ 0
Conversion of Series C Preferred Stock to Common Stock [Member] | Preferred Stock [Member] | Series C Preferred Stock [Member]
Statement [Line Items]
Conversion of stock (in shares)						(2,318,012)
Conversion of stock						$ (2,300)
Conversion of Series C Preferred Stock to Common Stock [Member] | Preferred Stock [Member] | Series D Preferred Stock [Member]
Statement [Line Items]
Conversion of stock (in shares)						0
Conversion of stock						$ 0
Conversion of Series C Preferred Stock to Common Stock [Member] | Common Stock [Member]
Statement [Line Items]
Conversion of stock (in shares)						77,267
Conversion of stock						$ 100
Conversion of Series C Preferred Stock to Common Stock [Member] | Additional Paid-in Capital [Member]
Statement [Line Items]
Conversion of stock						2,200
Conversion of Series C Preferred Stock to Common Stock [Member] | Treasury Stock, Common [Member]
Statement [Line Items]
Conversion of stock						0
Conversion of Series C Preferred Stock to Common Stock [Member] | Retained Earnings [Member]
Statement [Line Items]
Conversion of stock						0
Conversion of Series C Preferred Stock to Common Stock [Member]
Statement [Line Items]
Conversion of stock						$ 0
Preferred Stock [Member] | Series A Preferred Stock [Member]
Statement [Line Items]
Balances (in shares)		0		500,000	0	500,000
Balances		$ 0		$ 500	$ 0	$ 500
Net proceeds from exercise of warrants (in shares)						0
Net proceeds from exercise of warrants						$ 0
Accrued dividends on Series B Preferred stock						0
Stock-based compensation expense					$ 0	$ 0
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan (in shares)					0	0
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan					$ 0	$ 0
Issuance of common stock upon cashless exercise of stock options (in shares)					0	0
Issuance of common stock upon cashless exercise of stock options					$ 0	$ 0
Net proceeds from exercise of stock options for cash (in shares)					0	0
Net proceeds from exercise of stock options for cash					$ 0	$ 0
Issuance of common stock (in shares)
Issuance of common stock
Net loss					0	0
Issuance of common stock upon cashless exercise of stock options					0	$ 0
Increase in fair value attributable to warrant modification					$ 0
Fair value of common stock issued for acquisition of Pherin Pharmaceuticals, Inc. as an asset acquisition, net of registration expenses (in shares)					0
Fair value of common stock issued for acquisition of Pherin Pharmaceuticals, Inc. as an asset acquisition, net of registration expenses					$ 0
Balances (in shares)	0		0		0	0
Balances	$ 0		$ 0		$ 0	$ 0
Preferred Stock [Member] | Series B Preferred Stock [Member]
Statement [Line Items]
Balances (in shares)		0		1,131,669	0	1,131,669
Balances		$ 0		$ 1,100	$ 0	$ 1,100
Net proceeds from exercise of warrants (in shares)						0
Net proceeds from exercise of warrants						$ 0
Accrued dividends on Series B Preferred stock						0
Stock-based compensation expense					$ 0	$ 0
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan (in shares)					0	0
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan					$ 0	$ 0
Issuance of common stock upon cashless exercise of stock options (in shares)					0	0
Issuance of common stock upon cashless exercise of stock options					$ 0	$ 0
Net proceeds from exercise of stock options for cash (in shares)					0	0
Net proceeds from exercise of stock options for cash					$ 0	$ 0
Issuance of common stock (in shares)
Issuance of common stock
Net loss					0	0
Issuance of common stock upon cashless exercise of stock options					0	$ 0
Increase in fair value attributable to warrant modification					$ 0
Fair value of common stock issued for acquisition of Pherin Pharmaceuticals, Inc. as an asset acquisition, net of registration expenses (in shares)					0
Fair value of common stock issued for acquisition of Pherin Pharmaceuticals, Inc. as an asset acquisition, net of registration expenses					$ 0
Balances (in shares)	0		0		0	0
Balances	$ 0		$ 0		$ 0	$ 0
Preferred Stock [Member] | Series C Preferred Stock [Member]
Statement [Line Items]
Balances (in shares)		0		2,318,012	0	2,318,012
Balances		$ 0		$ 2,300	$ 0	$ 2,300
Net proceeds from exercise of warrants (in shares)						0
Net proceeds from exercise of warrants						$ 0
Accrued dividends on Series B Preferred stock						0
Stock-based compensation expense					$ 0	$ 0
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan (in shares)					0	0
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan					$ 0	$ 0
Issuance of common stock upon cashless exercise of stock options (in shares)					0	0
Issuance of common stock upon cashless exercise of stock options					$ 0	$ 0
Net proceeds from exercise of stock options for cash (in shares)					0	0
Net proceeds from exercise of stock options for cash					$ 0	$ 0
Issuance of common stock (in shares)
Issuance of common stock
Net loss					0	0
Issuance of common stock upon cashless exercise of stock options					0	$ 0
Increase in fair value attributable to warrant modification					$ 0
Fair value of common stock issued for acquisition of Pherin Pharmaceuticals, Inc. as an asset acquisition, net of registration expenses (in shares)					0
Fair value of common stock issued for acquisition of Pherin Pharmaceuticals, Inc. as an asset acquisition, net of registration expenses					$ 0
Balances (in shares)	0		0		0	0
Balances	$ 0		$ 0		$ 0	$ 0
Preferred Stock [Member] | Series D Preferred Stock [Member]
Statement [Line Items]
Balances (in shares)		0		402,149	0	402,149
Balances		$ 0		$ 400	$ 0	$ 400
Net proceeds from exercise of warrants (in shares)						0
Net proceeds from exercise of warrants						$ 0
Accrued dividends on Series B Preferred stock						0
Stock-based compensation expense					$ 0	$ 0
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan (in shares)					0	0
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan					$ 0	$ 0
Issuance of common stock upon cashless exercise of stock options (in shares)					0	0
Issuance of common stock upon cashless exercise of stock options					$ 0	$ 0
Net proceeds from exercise of stock options for cash (in shares)					0	0
Net proceeds from exercise of stock options for cash					$ 0	$ 0
Issuance of common stock (in shares)
Issuance of common stock
Net loss					0	0
Issuance of common stock upon cashless exercise of stock options					0	$ 0
Increase in fair value attributable to warrant modification					$ 0
Fair value of common stock issued for acquisition of Pherin Pharmaceuticals, Inc. as an asset acquisition, net of registration expenses (in shares)					0
Fair value of common stock issued for acquisition of Pherin Pharmaceuticals, Inc. as an asset acquisition, net of registration expenses					$ 0
Balances (in shares)	0		0		0	0
Balances	$ 0		$ 0		$ 0	$ 0
Common Stock [Member]
Statement [Line Items]
Balances (in shares)		6,889,221		6,025,042	6,889,221	6,025,042
Balances		$ 6,900		$ 6,000	$ 6,900	$ 6,000
Net proceeds from exercise of warrants (in shares)						243,293
Net proceeds from exercise of warrants						$ 200
Accrued dividends on Series B Preferred stock						0
Stock-based compensation expense					$ 0	$ 0
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan (in shares)					5,167	1,907
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan					$ 0	$ 0
Issuance of common stock upon cashless exercise of stock options (in shares)					3,646	4,204
Issuance of common stock upon cashless exercise of stock options					$ 0	$ 0
Net proceeds from exercise of stock options for cash (in shares)					3,700	6,019
Net proceeds from exercise of stock options for cash					$ 0	$ 0
Issuance of common stock (in shares)						50,593
Issuance of common stock						$ 100
Net loss					0	0
Issuance of common stock upon cashless exercise of stock options					0	$ 0
Increase in fair value attributable to warrant modification					$ 0
Fair value of common stock issued for acquisition of Pherin Pharmaceuticals, Inc. as an asset acquisition, net of registration expenses (in shares)					413,670
Fair value of common stock issued for acquisition of Pherin Pharmaceuticals, Inc. as an asset acquisition, net of registration expenses					$ 400
Balances (in shares)	7,315,404		6,889,221		7,315,404	6,889,221
Balances	$ 7,300		$ 6,900		$ 7,300	$ 6,900
Additional Paid-in Capital [Member]
Statement [Line Items]
Balances		336,280,500		315,777,900	336,280,500	315,777,900
Net proceeds from exercise of warrants						6,207,200
Accrued dividends on Series B Preferred stock						(945,100)
Stock-based compensation expense					3,336,400	3,480,700
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan					63,100	99,300
Issuance of common stock upon cashless exercise of stock options					0	0
Net proceeds from exercise of stock options for cash					104,400	140,000
Issuance of common stock						4,299,000
Net loss					0	0
Issuance of common stock upon cashless exercise of stock options					0	0
Increase in fair value attributable to warrant modification					77,400
Fair value of common stock issued for acquisition of Pherin Pharmaceuticals, Inc. as an asset acquisition, net of registration expenses					3,030,700
Balances	342,892,500		336,280,500		342,892,500	336,280,500
Treasury Stock, Common [Member]
Statement [Line Items]
Balances		(3,968,100)		(3,968,100)	(3,968,100)	(3,968,100)
Net proceeds from exercise of warrants						0
Accrued dividends on Series B Preferred stock						0
Stock-based compensation expense					0	0
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan					0	0
Issuance of common stock upon cashless exercise of stock options					0	0
Net proceeds from exercise of stock options for cash					0	0
Issuance of common stock						0
Net loss					0	0
Issuance of common stock upon cashless exercise of stock options					0	0
Increase in fair value attributable to warrant modification					0
Fair value of common stock issued for acquisition of Pherin Pharmaceuticals, Inc. as an asset acquisition, net of registration expenses					0
Balances	(3,968,100)		(3,968,100)		(3,968,100)	(3,968,100)
Retained Earnings [Member]
Statement [Line Items]
Balances		(267,604,000)		(219,841,600)	(267,604,000)	(219,841,600)
Net proceeds from exercise of warrants						0
Accrued dividends on Series B Preferred stock						0
Stock-based compensation expense					0	0
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan					0	0
Issuance of common stock upon cashless exercise of stock options					0	0
Net proceeds from exercise of stock options for cash					0	0
Issuance of common stock						0
Net loss					(59,247,700)	(47,762,400)
Issuance of common stock upon cashless exercise of stock options					0	0
Increase in fair value attributable to warrant modification					0
Fair value of common stock issued for acquisition of Pherin Pharmaceuticals, Inc. as an asset acquisition, net of registration expenses					0
Balances	(326,851,700)		(267,604,000)		(326,851,700)	(267,604,000)
Balances		64,715,300		91,978,500	64,715,300	91,978,500
Net proceeds from exercise of warrants						6,207,400
Accrued dividends on Series B Preferred stock						(945,100)
Stock-based compensation expense					3,336,400	3,480,700
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan					$ 63,100	$ 99,300
Issuance of common stock upon cashless exercise of stock options (in shares)					9,533	11,873
Issuance of common stock upon cashless exercise of stock options					$ 0	$ 0
Net proceeds from exercise of stock options for cash					104,400	140,000
Issuance of common stock						4,299,100
Net loss	(12,227,000)	$ (19,776,000)	(16,688,000)	$ (7,745,000)	(59,247,700)	(47,762,400)
Issuance of common stock upon cashless exercise of stock options					0	0
Increase in fair value attributable to warrant modification					77,400
Fair value of common stock issued for acquisition of Pherin Pharmaceuticals, Inc. as an asset acquisition, net of registration expenses					3,031,100
Balances	$ 12,080,000		$ 64,715,300		$ 12,080,000	$ 64,715,300

Note 1 - Description of Busines

Note 1 - Description of Business	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Description of Business Overview Vistagen Therapeutics, Inc., a Nevada corporation (which may Vistagen Company we our us CNS six five 101, NMDAR 101 not Our Product Candidates Pherine Product Candidates Five of our product candidates – fasedienol ( PH94B PH10 PH15, PH80 PH284 one PH15 PH80 PH284 Fasedienol Nasal Spray Fasedienol ( PH94B 3 SAD The proposed MOA of fasedienol is fundamentally differentiated from all currently approved anti-anxiety medications, including the three not 2 SAD PALISADE Phase 3 PALISADE- 1. May 2021, 3 1, 3 2020 19 1 2 SUDS In July 2022, 1. 1 1 not 1: 19 CRO may not 3 19 may 19 19, RSV PALISADE- 2. October 2021, 19 2, 1. July 2022, 1, 2 third 2 September 2022, 140 2, third 2 Although the results of the interim analysis of PALISADE- 2 not 1, 2, 2 140 2 second 2023. PALISADE Open Label Study. OLS 3, four no 1, not FDA Feedback on Path Forward; FEARLESS Program. first 2023, 3 3 LSAS NDA 3 Unlike the PALISADE Phase 3 six three Exploratory Phase 2A January 2023, 2A AjDA 2A 3.2 four four 71 41 34 four not not HAM-A four four Despite the methodological challenges inherent in the exploratory Phase 2A may Itruvone Nasal Spray Itruvone ( PH10 ADs not not may In January 2023, 1 three 2B June 2023, no The FDA has granted Fast Track designation for development of itruvone as a potential adjunctive treatment for MDD. PH80 PH80 PH80, 2A PH80 first p<.001 four 2B PH80 In addition, PH80 PH80 may PH15 PH15 PH15 1999 2 PH15 400 2 PH284 PH284 >10% 5 15 PH284 may second 2 AV- 101 AV- 101 4 101, 7 7 7 not 101 PK No 101 7 101 no no 4 Based on observations and findings from preclinical studies, we believe AV- 101 2A 101, one 101 The FDA has granted Fast Track designation for development of AV- 101 Acquisition of Pherin Pharmaceuticals, Inc. On December 20, 2022, Merger Agreement Merger Sub Pherin Pherin Acquisition February 2, 2023 ( Closing Date no As consideration for the Pherin Acquisition, we (i) issued an aggregate of 413,670 unregistered shares of our common stock having a fair value of approximately $3,076,550 at issuance to the exchange agent for the Pherin Acquisition, which shares were to approximately 96.07% of Pherin stockholders eligible to receive common stock in exchange for their outstanding shares of Pherin common stock (the Stock Consideration not Cash Consideration Merger Consideration Subsidiaries In addition to Pherin, as described above, Vistastem, Inc., a California corporation founded in 1998 Vistastem 10 Report Artemis April 2022, VistaStem Canada June 2022.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation and Going Concern	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Basis of Accounting [Text Block]	2. Basis of Presentation and Going Concern The accompanying Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles ( U.S. GAAP two As discussed more completely in Note 15, Subsequent Events 1 June 6, 2023 ( Reverse Split As a late-stage clinical-stage biopharmaceutical company having not May 1998) March 31, 2023. 101, Since our inception in May 1998 March 31, 2023 Recent Developments We did not March 31, 2023 ( Fiscal 2023 March 31, 2022 ( Fiscal 2022 May 2021, SM Sales Agreement Jefferies ATM may, September October 2021, not 2023. 15, Subsequent Events June 12, 2023 During our fiscal year ended March 31, 2021 ( Fiscal 2021 AffaMed Agreement, 11, Licensing, Sublicensing and Collaborative Agreements.) 2023, 2019 2019 ESPP We had cash and cash equivalents of approximately $16.6 million at March 31, 2023, not twelve 2B 1 101 2A 101. not When necessary and advantageous, we will seek additional financial resources to fund our planned operations through (i) sales of our equity and/or debt securities in one may PH94B may no 3 S- 3 one may 3 not During the next twelve 3 2B 2B PH80, PH15 PH284 2A 101 one Our future working capital requirements will depend on many factors, including, without limitation, potential impacts related to adjustments in the size of our staff, the scope and nature of opportunities related to our success or failure and the success or failure of certain other companies in nonclinical and clinical trials, including the development and commercialization of our current product candidates, and the availability of, and our ability to enter into financing transactions and research, development and commercialization collaborations on terms acceptable to us. In the future, to further advance the clinical development of our product candidates, as well as support our operating activities, we plan to seek additional financing, including both equity-based capital and funding from non-dilutive sources, and continue to carefully manage our operating costs, including, but not Notwithstanding the foregoing, there can be no September 6, 2022, Nasdaq 30 not $1.00 March 6, 2023, 180 not March 7, 2023, second 180 September 5, 2023, 10 June 7, 2023. June 22, 2023 no

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles ( U.S. GAAP not Cash and Cash Equivalents Cash and cash equivalents are considered to be highly liquid investments with maturities of three Property and Equipment Property and equipment is stated at cost, net of accumulated depreciation. Repairs and maintenance costs are expensed in the period incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of laboratory, information technology and office equipment range from three seven five ten Impairment of Long-Lived Assets Our long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not not not Deferred Offering Costs Deferred offering costs include registration expenses related to our current S- 3 Shelf Registration March 26, 2021, 8, Capital Stock June 2021, March 31, 2022. Revenue Recognition The AffaMed Agreement, involving clinical development and commercialization of fasedienol for acute treatment of anxiety in adults with SAD, and potentially other anxiety-related disorders, in Greater China, South Korea, and Southeast Asia, has been the basis of our reported revenue for both Fiscal 2023 2022. August 2020, Under ASC Topic 606, 606, five five Once a contract is determined to be within the scope of Topic 606, may We assess whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) our promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct in the evaluation of a collaboration arrangement subject to Topic 606, not The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices ( SSP not may If the consideration promised in a contract includes a variable amount, we estimate the amount of consideration to which we will be entitled in exchange for transferring the promised goods or services to a customer. We determine the amount of variable consideration by using the expected value method or the most likely amount method. We include the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not If an arrangement includes development and regulatory milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not not not In determining the transaction price, we adjust consideration for the effects of the time value of money if the timing of payments provides us with a significant benefit of financing. We do not one We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, based on the use of an output or input method. Research and Development Expenses Research and development expenses are composed of both internal and external costs. Internal costs include salaries and employment-related expenses, including stock-based compensation expense, of scientific personnel and direct project costs. External research and development expenses consist primarily of costs associated with clinical and nonclinical development of fasedienol, itruvone and AV- 101. We also record accruals for estimated ongoing clinical trial costs. Clinical trial costs represent costs incurred by contract research organizations ( CRO Costs incurred in obtaining product or technology licenses are charged immediately to research and development expense if, at acquisition, the product or technology licensed has not no three March 31, 2023. Stock-Based Compensation We recognize compensation cost for all stock-based awards to employees and non-employee consultants based on the grant date fair value of the award. We record stock-based compensation expense over the period during which the employee or other grantee is required to perform services in exchange for the award, which generally represents the scheduled vesting period. We have not Income Taxes We account for income taxes using the asset and liability approach promulgated by ASC 740, Income Taxes Right-of-use Assets and Operating Lease Obligations We account for our leases following the guidance of Accounting Standards Update No. 2016 02, Leases (Topic 842 ASU 2016 02 2016 02 Right-of-use assets not may Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 not Financing leases, formerly referred to as capitalized leases, are treated similarly to operating leases except that the asset subject to the lease is included in the appropriate fixed asset category, rather than recorded as a Right-of-use asset, and depreciated over its estimated useful life, or lease term, if shorter. Concentrations of Credit Risk Financial instruments, which potentially subject us to concentrations of credit risk, consist of cash and cash equivalents. Our investment policies limit any such investments to short-term, low-risk instruments. We deposit cash and cash equivalents with financial institutions which are insured to the maximum of federal limitations. Balances in these accounts may Fair Value Measurements We do not not three • Level 1 1 • Level 2 1 not • Level 3 i.e., no 3 A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Where quoted prices are available in an active market, securities are classified as Level 1 not 3 March 31, 2023 2022, 1 March 31, 2023 March 31, 2022. Warrants Issued in Connection with Equity Financing We evaluate the appropriate balance sheet classification of warrants we issue as either equity or as a derivative liability. In accordance with ASC 815 40, Derivatives and Hedging-Contracts in the Entity s Own Equity ASC 815 40 not not 480, Distinguishing Liabilities from Equity 815 40, March 31, 2023 2022 Comprehensive Loss We have no Loss per Common Share Attributable to Common Stockholders Basic net loss attributable to common stockholders per share of common stock excludes the effect of dilution and has historically been computed by dividing net loss increased by the accrual of dividends on outstanding shares of our Series B 10% Convertible Preferred Stock ( Series B Preferred third 2022, As a result of our net loss for both years presented and the conversion of all series of our preferred stock prior to March 31, 2022, March 31, 2023 2022 At March 31, At March 31, 2023 2022 Outstanding options under the Company's Amended and Restated 2016 (formerly 2008) Stock Incentive Plan and 2019 Omnibus Equity Incentive Plan 702,545 646,213 Outstanding warrants to purchase common stock 45,685 309,195 Total 748,230 955,408 Recent Accounting Pronouncements We believe the following recent accounting pronouncements or changes in accounting pronouncements are of significance or potential significance to the Company. In August 2020, FASB 2020 06, Debt with Conversion and Other Options (Subtopic 470 20 Contracts in Entity s Own Equity 815 40 ASU 2020 06 The guidance in ASU 2020 06 470 20, 470 20 not In addition, the amendments revise the scope exception from derivative accounting in ASC 815 40 not The amendments in ASU 2020 06 260, Earnings Per Share may The amendments in ASU 2020 06 April 1, 2024. not 2020 06 Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not not

Note 4 - Prepaid Expenses and O

Note 4 - Prepaid Expenses and Other Current Assets	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Prepaid Expenses and Other Current Assets Disclosure [Text Block]	4. Prepaid expenses and other current assets are composed of the following: March 31, March 31, 2023 2022 Clinical and nonclinical materials and contract services $ 166,700 $ 2,139,600 Insurance 206,000 196,500 Receivable from CRO for cancelled project - 337,900 Receivable from collaboration partner 274,700 - All other 155,300 71,800 $ 802,700 $ 2,745,800 The amount reported as receivable from CRO for cancelled project at March 31, 2022 July 2022. March 31, 2023

Note 5 - Property and Equipment

Note 5 - Property and Equipment, Net	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and Equipment, Net Property and equipment, net is composed of the following: March 31, March 31, 2023 2022 Laboratory equipment $ 1,234,800 $ 1,181,300 Tenant improvements 214,400 214,400 Office furniture and equipment 40,300 76,200 Manufacturing equipment 211,200 211,200 1,700,700 1,683,100 Accumulated depreciation and amortization (1,193,400 ) (1,268,800 ) Property and equipment, net $ 507,300 $ 414,300 The amounts reported above for manufacturing equipment at March 31, 2023 2022 fourth 2021. Included in amounts reported above for office furniture and equipment is the right-of-use asset related to a financing lease of certain office equipment. Amounts associated with assets subject to the financing lease at March 31, 2023 2022 March 31, March 31, 2023 2022 Office equipment subject to financing lease $ 10,600 $ 14,700 Accumulated depreciation (2,000 ) (14,700 ) Net book value of office equipment subject to financing lease $ 8,600 $ - The fully depreciated office equipment reported at March 31, 2022 January 2022. April 2022. June 2027. none third March 31, 2023 2022. The following table summarizes depreciation and amortization expense attributable to owned and leased property and equipment for the fiscal years ended March 31, 2023 2022: Fiscal Years Ended March 31, 2023 2022 Owned assets $ 127,500 $ 151,200 Leased assets 2,000 2,300 Total depreciation and amortization $ 129,500 $ 153,500

Note 6 - Accrued Expenses

Note 6 - Accrued Expenses	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued Expenses Accrued expenses are composed of the following: March 31, March 31, 2023 2022 Accrued expenses for clinical and nonclinical materials, development and contract services $ 412,100 $ 1,070,800 Accrued compensation 337,200 66,200 Accrued professional services 38,100 159,500 All other - 32,700 $ 787,400 $ 1,329,200 In both periods, accrued expenses for clinical and nonclinical services includes accrued clinical trial expenses and other amounts accrued for contract manufacturing and product development services. Accrued compensation at March 31, 2023

Note 7 - Note Payable

Note 7 - Note Payable	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Debt Disclosure [Text Block]	7. Note Payable The following table summarizes our outstanding note payable at March 31, 2023 2022: March 31, 2023 March 31, 2022 Principal Accrued Principal Accrued Balance Interest Total Balance Interest Total 3.88 $ 105,300 $ - $ 105,300 $ - $ - $ - In May 2022, 3.88% April 2023.

Note 8 - Capital Stock

Note 8 - Capital Stock	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Equity [Text Block]	8. Capital Stock Common Stock At our Special Meeting of Stockholders on March 5, 2021, may March 5, 2021, May 2016, May 11, 2016. Series A Preferred Stock In December 2011, Series A Preferred one twentieth 1/20 one At March 31, 2021, November 2021, November 2022, Series B Preferred Stock In July 2014, Series B Preferred May 2015, Series B Certificate of Designation Each share of Series B Preferred was convertible, at the option of the holder ( Conversion one thirtieth 1/30 one May 2016, Prior to Conversion, shares of Series B Preferred accrued in-kind dividends (payable only in unregistered shares of our common stock) at a rate of 10% per annum ( Accrued Dividends March 31, 2021, November 2021, May 2015 November 2021, April 2021 November 2021 March 31, 2022. November 2022, Series C Preferred Stock In January 2016, Series C Preferred Certificate of Designation Series C Preferred Each share of Series C Preferred was convertible, at the option of the holder into one- thirtieth 1/30 one March 31, 2021, one October 2021, November 2022, Series D Preferred Stock On December 17, 2020, Series D Preferred Series D Certificate of Designation December 21, 2020. Each share of our Series D Preferred was initially convertible into approximately 0.7667 ( 23/30 one not Approval Date March 5, 2021. March 12, 2021 March 31, 2021, March 31, 2021, April 2021, December 2020 November 2022, At March 31, 2022 2023, Financing Transactions We did not 2023. 2022. Open Market Sale Agreement In May 2021, SM Sales Agreement Jefferies ATM may, Shares three may 415 4 1933, may may not may 3 March 15, 2021 March 26, 2021. In transactions occurring during September 2021 October 1, 2021, not 2023. 15, Subsequent Events March 31, 2023. May 2021 March 31, 2023, 2022 none 2023. Stock Option Exercises and Employee Stock Purchase Plan Purchases During Fiscal 2023, 2022, June 30, 2022 December 30, 2022, 2019 June 30, 2021 December 31, 2021, 2019 Warrant Exercises, Expirations and Modifications There were no warrant exercises during Fiscal 2023; 2023. 2022, On December 5, 2022, December 9, 2022 two No March 31, 2023 Assumption: Pre-modification Post-modification Market price per share $ 3.74 $ 3.74 Exercise price per share $ 15.00 $ 15.00 Risk-free interest rate 3.93 % 4.41 % Remaining contractual term in years 0.011 2.012 Volatility 65.60 % 175.27 % Dividend rate 0.0 % 0.0 % Number of warrant shares 33,333 33.333 Weighted average fair value per share $ 0.00 $ 2.40 The following table summarizes outstanding and exercisable warrants to purchase shares of our common stock as of March 31, 2023. March 31, 2023 Exercise Warrants Outstanding Price Expiration and Exercisable at per Share Date March 31, 2023 $15.00 12/9/2024 33,333 $21.90 7/25/2025 12,352 45,685 At March 31, 2023, No Reserved Shares At March 31, 2023, Pursuant to warrants to purchase common stock: Subject to outstanding warrants 45,685 Pursuant to stock incentive plans: Subject to outstanding options under the Amended and Restated 2016 Stock Incentive Plan and the Amended and Restated 2019 Omnibus Equity Incentive Plan 702,545 Available for future grants under the Amended and Restated 2019 Omnibus Equity Incentive Plan 179,260 Available for future issuance under the 2019 Employee Stock Purchase Plan 24,322 906,127 Reserved for issuance under the Sales Agreement 858,498 Total 1,810,310 At March 31, 2023, not

Note 9 - Research and Developme

Note 9 - Research and Development Expenses	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Research, Development, and Computer Software Disclosure [Text Block]	9. Research and Development Expenses We recorded research and development expenses of approximately $44.4 million and $35.4 million in Fiscal 2023 2022, 2023 2022, 2023, 101

Note 10 - Income Taxes

Note 10 - Income Taxes	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	10. Income Taxes The provision for income taxes for the periods presented in the Consolidated Statements of Operations and Comprehensive Loss represents minimum California franchise tax, North Carolina and Utah income tax. Income tax expense (benefit) differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax income (loss) as a result of the following: Fiscal Years Ended March 31, 2023 2022 Computed expected tax benefit (21.00 )% (21.00 )% State income taxes, net of federal benefit 0.00 % 0.01 % Tax effect of warrant modifications 0.03 % 0.00 % Tax effect of research and development credits (0.78 % (0.73 % Tax effect of stock compensation 0.50 % 0.59 % Tax effect of other non-deductible items 1.27 % 0.11 % Expired net operating loss carryforwards 0.17 % 0.74 % Change in valuation allowance (federal only) 18.57 % 20.40 % All other 1.24 % 0.00 % Income tax expense 0.00 % 0.12 % Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities are as follows: March 31, 2023 2022 Deferred tax assets: Net operating loss carryovers $ 43,602,800 $ 41,924,800 Basis differences in property and equipment - 47,000 Research and development credit carryforwards 3,591,100 3,032,800 Stock based compensation 2,985,600 3,469,300 Operating lease Right-of-Use asset 73,200 79,700 Capitalized research and development costs 8,214,700 - Deferred revenue 642,500 - Accruals and reserves 146,300 66,700 Total deferred tax assets 59,256,100 48,620,300 Valuation allowance (59,251,300 ) (48,620,300 ) Total deferred tax assets net of valuation allowance 4,800 - Deferred tax liabilities: Basis differences in property and equipment (4,800 ) - Total deferred tax liabilities (4,800 ) - Net deferred tax asset (liability) $ - $ - Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $10,631,000 and $8,743,700 during the fiscal years ended March 31, 2023 2022, As of March 31, 2023, March 31, 2018 March 31, 2024 March 31, 2038. March 31, 2018 March 31, 2023, 2029 2043. March 31, 2029, not The Tax Cuts and Jobs Act of 2017 TCJA 174 December 31, 2021. five 15 March 31, 2023. On March 27, 2020 December 21, 2020, 2021 not On June 29, 2020, 85 85 2020 2023. February 9, 2022, 113 113 2022 January 1, 2022, not U.S. federal and state tax laws include substantial restrictions on the utilization of net operating loss carryforwards in the event of an ownership change of a corporation. We have not 1998 may not We file income tax returns in the U.S. federal, and various U.S. state jurisdictions. We are subject to U.S. federal and state income tax examinations by tax authorities for tax years 2004 2023 not Uncertain Tax Positions Our unrecognized tax benefits at March 31, 2023 2022 March 31, 2023 2022 none Fiscal Years Ended March 31, 2023 2022 Unrecognized benefit - beginning of period $ 1,088,100 $ 931,900 Current period tax position increases 194,900 156,200 Unrecognized benefit - end of period $ 1,283,000 $ 1,088,100 Our policy is to recognize interest and penalties related to income taxes as components of interest expense and other expense, respectively. We incurred no March 31, 2023 2022. not twelve

Note 11 - Licensing, Sublicensi

Note 11 - Licensing, Sublicensing and Collaborative Agreements	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	11. Licensing, Sublicensing and Collaborative Agreements Fasedienol Sublicense Agreement with EverInsight Therapeutics, Inc. (now AffaMed Therapeutics, Inc.) On June 24, 2020, EverInsight October 2020, Territory Under the terms of the AffaMed Agreement, AffaMed is responsible for all costs related to developing, obtaining regulatory approval of, and commercializing fasedienol for treatment of SAD, and potentially other anxiety-related indications, in the Territory. A joint development committee has been established between AffaMed and us to coordinate and review the development and commercialization plans with respect to fasedienol in the Territory. We are responsible for pursuing clinical development and regulatory submissions of fasedienol for acute treatment of anxiety in adults with SAD, and potentially other anxiety-related indications, in the United States on a ‘‘best efforts’’ basis, with no 3 Under the terms of the AffaMed Agreement, AffaMed paid us a non-refundable upfront license payment of $5.0 million in August 2020. ten no may We have determined that we have one not Development and commercialization milestones were not We recognize revenue as the combined performance obligation is satisfied over time using an output method. The measure of progress is stand-ready straight-line over the period in which we expect to perform the services related to the sublicense of fasedienol. Significant management judgment is required to determine the level of effort attributable to the performance obligation included in the AffaMed Agreement and the period over which we expect to complete our performance obligation under the arrangement. The performance period or measure of progress was estimated at the inception of the arrangement and is re-evaluated in subsequent reporting periods. This re-evaluation may 1 PH94B, September 30, 2022, 2027 2024. not 3, Summary of Significant Accounting Policies September 30, 2022 $892,600 2023. March 31, 2023, 2022. March 31, 2023, The following table presents changes in our contract liabilities for Fiscal 2022 2023: Revenue Balance at Recognition Balance at March 31, 2021 Amortization Derecognition March 31, 2022 Deferred revenue - current portion $ 1,420,200 $ (176,200 ) $ - $ 1,244,000 Deferred revenue - non-current portion 2,490,300 (932,700 ) - 1,557,600 Total $ 3,910,500 $ (1,108,900 ) $ - $ 2,801,600 Revenue Balance at Recognition Balance at March 31, 2022 Amortization Derecognition March 31, 2023 Deferred revenue - current portion $ 1,244,000 $ (665,300 ) $ 135,600 $ 714,300 Deferred revenue - non-current portion 1,557,600 - 757,000 2,314,600 Total $ 2,801,600 $ (665,300 ) $ 892,600 $ 3,028,900 Contract Acquisition Costs During the quarter ended September 30, 2020, June 24, 2020, 7,788 September 2022 2023 2022, Unless earlier terminated due to certain material breaches of the contract, or otherwise, the AffaMed Agreement will expire on a jurisdiction-by-jurisdiction basis until the latest to occur of the expiration of the last valid claim under a licensed patent of fasedienol in such jurisdiction, the expiration of regulatory exclusivity in such jurisdiction or ten first License Agreements with Pherin Pharmaceuticals, Inc. (Pherin) In September 2018, October 2018, no

Note 12 - Stock Option Plans, E

Note 12 - Stock Option Plans, Employee Stock Purchase Plan, and 401(k) Plan	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	12. Stock Option Plans, Employee Stock Purchase Plan, and 401 At March 31, 2023, ● Amended and Restated 2016 2016 ● Amended and Restated 2019 2019 Description of the 2016 Our Board unanimously approved the Company’s Amended and Restated 2016 2008 2016 July 26, 2016, 2016 2016 September 26, 2016, 2017 September 15, 2017. 2016 2016 422 1986, Code 2016 March 31, 2023. 2019 no 2016 2019 2016 Description of the Amended 2019 Our Board approved the Vistagen Therapeutics, Inc. 2019 2019 May 27, 2019, September 5, 2019. June 28, 2021 September 17, 2021, 2019 Amended 2019 2019 Awards and Eligible Participants The Amended 2019 may 2019 The Amended 2019 SARs may 2019 may one Plan Administration The Amended 2019 Committee may may The Committee sets stock option exercise prices and terms, except that stock options must be granted with an exercise price not 100% may 422 ten The Committee may 2019 The Committee may may may may The Committee may may may may March 31, 2023, not Authorized Shares A total of 250,000 shares of our common stock was initially authorized for issuance under the 2019 2019 2019 In the event any award under the Amended 2019 2019 2019 Vesting No 2019 may This requirement does not not not may no Option Repricing The Amended 2019 not Change of Control In the event of a change in control of the Company, the Committee may may 2019 Termination Unless earlier terminated by the Board, the Amended 2019 no may September 5, 2029, ten 2019 may 2019 2019 2019 may not, During Fiscal 2023, 2019 ● Options to purchase 96,667 shares granted to all of our employees except executive officers and members of our Board in November 2022, first three ● Options to purchase 33,900 shares granted to newly hired employees at exercise prices ranging from $3.57 per share to $45.30 per share. Options granted to new employees vest 25% on the first three ● Options to purchase 13,333 shares granted to consultants, which options vested 25% on the grant date and ratably monthly over the next twelve During Fiscal 2022, 2019 ● Options to purchase 136,333 shares of our common stock granted to our officers and employees, of which options to purchase 55,000 shares were granted to newly-hired employees upon commencement of their employment. Options granted to newly-hired employees vest 25% on the first three March 2022, may 2022, two ● Options to purchase 24,167 shares of our common stock granted to the independent members of our Board, of which 7,500 were granted to three one ● Options to purchase 13,000 shares of our common stock granted to certain consultants, which options were vested 25% upon grant with the balance generally vesting over one two On September 12, 2022, 44,071shares September 13, 2022, 90 No 2023. Assumption: Pre-modification Post-modification Market price per share $ 6.156 $ 6.156 Exercise price per share $ 38.10 $ 38.10 Risk-free interest rate 2.62 % 3.17 % Remaining contractual term in years 0.003 0.249 Volatility 138.31 % 412.67 % Dividend rate 0.0 % 0.0 % Number of option shares 44,071 44,071 Weighted average fair value per share $ 0.00 $ 2.46 On December 12, 2022, March 31, 2023. No 2023, 2023. Assumption: Pre-modification Post-modification Market price per share $ 3.57 $ 3.57 Exercise price per share $ 38.10 $ 38.10 Risk-free interest rate 3.86 % 4.38 % Remaining contractual term in years 0.0 0.299 Volatility 92.75 % 99.54 % Dividend rate 0.0 % 0.0 % Number of option shares 44,071 44,071 Weighted average fair value per share $ 0.00 $ 0.002 The following table summarizes stock-based compensation expense related to option grants to our officers, independent directors, consultants and service providers included in the accompanying Consolidated Statements of Operations and Comprehensive Loss for the years ended March 31, 2023 2022, Fiscal Years Ended March 31, 2023 2022 Research and development expense $ 1,364,800 $ 1,457,600 General and administrative expense 1,971,600 2,023,100 Total stock-based compensation expense $ 3,336,400 $ 3,480,700 Expense amounts reported above include $37,000 and $47,000 in research and development expense for the fiscal years ended March 31, 2023 2022, March 31, 2023 2022, 2019 2019 We used the Black-Scholes Option Pricing model with the following weighted average assumptions to determine stock-based compensation expense related to option grants during the fiscal years ended March 31, 2023 2022: Fiscal Years Ended March 31, 2023 2022 (weighted average) (weighted average) Exercise price $ 10.20 $ 53.40 Market price on date of grant $ 10.20 $ 53.40 Risk-free interest rate 3.55 % 1.42 % Expected term (years) 6.03 5.60 Volatility 158.03 % 80.27 % Expected dividend yield 0.00 % 0.00 % Fair value per share at grant date $ 8.10 $ 36.00 The expected term of options represents the period that our stock-based compensation awards are expected to be outstanding. We have calculated the weighted-average expected term of the options using the simplified method as prescribed by Securities and Exchange Commission Staff Accounting Bulletins No. 107 No. 110 SAB No. 107 110 No. 107 110 not not not The following table summarizes stock option activity for the fiscal years ended March 31, 2023 2022 2019 2016 Fiscal Years Ended March 31, 2023 2022 Weighted Weighted Average Average Number of Exercise Number of Exercise Shares Price Shares Price Options outstanding at beginning of period 646,213 $ 44.10 487,936 $ 40.20 Options granted 143,900 $ 10.20 173,500 $ 53.40 Options exercised (9,533 ) $ 18.30 (11,873 ) $ 24.30 Options forfeited (32,660 ) $ 42.30 (3,333 ) $ 59.70 Options expired (45,374 ) $ 40.80 (17 ) $ 240.00 Options outstanding at end of period 702,545 $ 37.80 646,213 $ 44.10 Options exercisable at end of period 496,257 $ 42.00 452,309 $ 39.60 Weighted average grant-date fair value of options granted during the period $ 8.10 $ 36.00 The following table summarizes information on stock options outstanding and exercisable under the Amended 2019 2016 March 31, 2022: Options Outstanding Options Exercisable Weighted Average Weighted Weighted Remaining Average Average Exercise Number Years until Exercise Number Exercise Price Outstanding Expiration Price Exercisable Price $ 3.57 to $12.30 151,773 8.96 $ 6.47 43,710 $ 11.24 $12.60 to $36.30 128,521 6.06 $ 29.35 117,097 $ 29.41 $38.10 to $41.10 130,833 8.26 $ 40.40 93,042 $ 40.31 $42.30 to $51.00 147,833 4.95 $ 44.74 144,500 $ 44.72 $52.50 to $277.50 143,585 7.89 $ 68.76 97,908 $ 68.34 702,545 7.24 $ 37.76 496,257 $ 41.99 At March 31, 2023, 2019 Aggregate intrinsic value is the sum of the amount by which the fair value of the underlying common stock exceeds the aggregate exercise price of the outstanding options ( in-the-money-options March 31, 2023, As of March 31, 2023, 2019 2016 May 2025. 2019 Our Board approved the Vistagen Therapeutics, Inc. 2019 2019 June 13, 2019. 2019 September 5, 2019. 2019 The 2019 423 2019 2019 may 2019 The 2019 first January 1, 2020 June 30, 2020, first January July June December, may not 423 5 27 On the first Grant Date 2019 may Each participant’s payroll deductions under the 2019 2019 March 31, 2023 2022 Each option granted under the 2019 Exercise Date 2019 85% 85% 2019 No 2019 Participation in the 2019 ● A participant cannot contribute less than 1% or more than 15% of his or her compensation to the purchase of stock under the 2019 one ● A participant cannot accrue rights to purchase more than $25,000 ● A participant will not 2019 5.0% one The $25,000 5% As is customary, the number of shares of stock available under the 2019 2019 2019 may not The Board generally may 2019 2019 No 2019 may 2019 Our 2019 January 1, 2020 2019 December 31, 2030, 2023, 2019 2022, 401 Through a third 401 may not

Note 13 - Related Party Transac

Note 13 - Related Party Transactions	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	13. Related Party Transactions During the fourth 2022, March 31, 2022 2023, March 31, 2023. June 2023, December 31, 2023. On November 11, 2022, i3 March 31, 2024, i3 March 31, 2023 December 31, 2022 2023. June 2023, December 31, 2023. On December 1, 2022, December 31, 2022, December 31, 2023. 2023, March 31, 2023 During the quarter ended December 31, 2021, 101. December 31, 2021 December 31, 2021, fourth 2022.

Note 14 - Commitments, Continge

Note 14 - Commitments, Contingencies, Guarantees and Indemnifications	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	14. Commitments, Contingencies, Guarantees and Indemnifications From time to time, we may not We indemnify our officers and directors for certain events or occurrences while the officer or director is or was serving at our request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. We will indemnify the officers or directors against any and all expenses incurred by the officers or directors because of their status as one may no March 31, 2023 2022. In the normal course of business, we provide indemnifications of varying scopes under agreements with other companies, typically clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, we generally indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with the use or testing of our product candidates or with any U.S. patents or any copyright or other intellectual property infringement claims by any third not March 31, 2023 2022. Leases Financing Lease Assets subject to financing lease obligations at March 31, 2023 2022 March 31, March 31, 2023 2022 Office equipment subject to financing lease $ 10,600 $ 14,700 Accumulated depreciation (2,000 ) (14,700 ) Net book value of office equipment subject to financing lease $ 8,600 $ - The fully depreciated office equipment reported at March 31, 2022 January 2022. April 2022. Fiscal Year Ending March 31, 2024 $ 2,900 2025 2,900 2026 2,900 2027 2,900 2028 600 Future minimum lease payments 12,200 Less imputed interest included in minimum lease payments (3,100 ) Present value of minimum lease payments 9,100 Less current portion (1,700 ) Financing lease obligation - non-current portion $ 7,400 Amortization expense for assets recorded under financing leases is included in depreciation expense. Operating Lease We lease our headquarters office and laboratory space in South San Francisco, California under the terms of a lease that was set to expire on July 31, 2022 five August 2022 July 2027 842. October 14, 2021, Lease Amendment August 1, 2022 July 31, 2027 five five August 1, 2027. ASC 842 April 1, 2019, not 842. The following table summarizes the presentation of the operating lease in our Consolidated Balance Sheets at March 31, 2023 2022: As of March 31, 2023 As of March 31, 2022 Assets Right-of-use asset – operating lease $ 2,260,300 $ 2,662,000 Liabilities Current operating lease obligation $ 485,600 $ 433,300 Non-current operating lease obligation 2,119,800 2,605,400 Total operating lease liability $ 2,605,400 $ 3,038,700 The following table summarizes the effect of operating lease costs in our consolidated statements of operations: For the Fiscal Year Ended For the Fiscal Year Ended March 31, 2023 March 31, 2022 Operating lease cost $ 851,700 $ 725,000 The minimum (base rental) lease payments related to our South San Francisco operating lease are expected to be as follows: Fiscal Years Ending March 31, Amount 2024 $ 689,500 2025 710,200 2026 731,500 2027 753,500 2028 253,600 Total lease expense 3,138,300 Less imputed interest (532,900 ) Present value of operating lease liabilities $ 2,605,400 The remaining lease term, which does not five July 31, 2027, As of March 31, 2023 Assumed remaining lease term in years 4.33 Assumed discount rate 8.54% The interest rate implicit in lease contracts is typically not 842, Supplemental disclosure of cash flow information related to our operating leases included in cash flows used by operating activities in the consolidated statements of cash flows is as follows: For the Fiscal Year Ended For the Fiscal Year Ended March 31, 2023 March 31, 2022 Cash paid for amounts included in the measurement of lease liabilities $ 883,200 $ 844,300 During Fiscal 2023 2022, not We also lease a small office in the San Francisco Bay Area under a month-to-month arrangement at insignificant cost and have made an accounting policy election not 842 2023 2022

Note 15 - Subsequent Events

Note 15 - Subsequent Events	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	15. Subsequent Events We have evaluated subsequent events through the date of this Annual Report and have identified the following material events and transactions that occurred after March 31, 2023: Reverse Split of Common Stock On June 6, 2023, one thirty 1 Reverse Stock Split 2022 October 28, 2022, one one June 7, 2023. 2016 2019 2019 Sales of Common Stock under the Sales Agreement During June 2023 Grant of Options from 2019 In June 2023, 2019 five 30

Note 16 - Supplemental Financia

Note 16 - Supplemental Financial Information (Unaudited)	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Quarterly Financial Information [Text Block]	16. The following table presents the unaudited statements of operations data for each of the eight March 31, 2023. not Quarterly Results of Operations (Unaudited) (in thousands, except share and per share amounts) Three Months Ended June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 Total Fiscal Year 2023 Sublicense revenue $ 310 $ (893 ) $ 180 $ 176 $ (227 ) Total revenue 310 (893 ) 180 176 (227 ) Operating expenses: Research and development 15,291 12,895 6,854 9,337 44,377 General and administrative 4,792 3,702 3,092 3,078 14,664 Total operating expenses 20,083 16,597 9,946 12,415 59,041 Loss from operations (19,773 ) (17,490 ) (9,766 ) (12,239 ) (59,268 ) Other income and expenses, net: Interest income, net 2 6 5 13 26 Loss before income taxes (19,771 ) (17,484 ) (9,761 ) (12,226 ) (59,242 ) Income taxes (5 ) - - (1 ) (6 ) Net loss and comprehensive loss (19,776 ) (17,484 ) (9,761 ) (12,227 ) (59,248 ) Basic and diluted net loss per common share $ (2.87 ) $ (2.54 ) $ (1.42 ) $ (1.71 ) $ (8.51 ) Weighted average shares used in computing basic and diluted net loss per common share 6,886,557 6,893,708 6,894,603 7,163,799 6,958,749 Three Months Ended June 30, 2021 September 30, 2021 December 31, 2021 March 31, 2022 Total Fiscal Year 2022 Sublicense revenue $ 354 $ 358 $ 358 $ 39 $ 1,109 Total revenue 354 358 358 39 1,109 Operating expenses: Research and development 5,458 9,937 7,779 12,234 35,408 General and administrative 2,643 3,221 3,118 4,498 13,480 Total operating expenses 8,101 13,158 10,897 16,732 48,888 Loss from operations (7,747 ) (12,800 ) (10,539 ) (16,693 ) (47,779 ) Other income and expenses, net: Interest income, net 5 5 5 5 20 Loss before income taxes (7,742 ) (12,795 ) (10,534 ) (16,688 ) (47,759 ) Income taxes (3 ) - - - (3 ) Net loss and comprehensive loss (7,745 ) (12,795 ) (10,534 ) (16,688 ) (47,762 ) Accrued dividend on Series B Preferred stock (362 ) (375 ) (208 ) - (945 ) Net loss attributable to common stockholders $ (8,107 ) $ (13,170 ) $ (10,742 ) $ (16,688 ) $ (48,707 ) Basic and diluted net loss per common share attributable to common stockholders $ (1.28 ) $ (2.04 ) $ (1.59 ) $ (2.42 ) $ (7.38 ) Weighted average shares used in computing basic and diluted net loss per common share attributable to common stockholders 6,330,805 6,440,928 6,744,289 6,884,403 6,599,287

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles ( U.S. GAAP not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash and cash equivalents are considered to be highly liquid investments with maturities of three
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment is stated at cost, net of accumulated depreciation. Repairs and maintenance costs are expensed in the period incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of laboratory, information technology and office equipment range from three seven five ten
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets Our long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not not not
Stockholders' Equity, Policy [Policy Text Block]	Deferred Offering Costs Deferred offering costs include registration expenses related to our current S- 3 Shelf Registration March 26, 2021, 8, Capital Stock June 2021, March 31, 2022.
Revenue [Policy Text Block]	Revenue Recognition The AffaMed Agreement, involving clinical development and commercialization of fasedienol for acute treatment of anxiety in adults with SAD, and potentially other anxiety-related disorders, in Greater China, South Korea, and Southeast Asia, has been the basis of our reported revenue for both Fiscal 2023 2022. August 2020, Under ASC Topic 606, 606, five five Once a contract is determined to be within the scope of Topic 606, may We assess whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) our promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct in the evaluation of a collaboration arrangement subject to Topic 606, not The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices ( SSP not may If the consideration promised in a contract includes a variable amount, we estimate the amount of consideration to which we will be entitled in exchange for transferring the promised goods or services to a customer. We determine the amount of variable consideration by using the expected value method or the most likely amount method. We include the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not If an arrangement includes development and regulatory milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not not not In determining the transaction price, we adjust consideration for the effects of the time value of money if the timing of payments provides us with a significant benefit of financing. We do not one We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, based on the use of an output or input method.
Research, Development, and Computer Software, Policy [Policy Text Block]	Research and Development Expenses Research and development expenses are composed of both internal and external costs. Internal costs include salaries and employment-related expenses, including stock-based compensation expense, of scientific personnel and direct project costs. External research and development expenses consist primarily of costs associated with clinical and nonclinical development of fasedienol, itruvone and AV- 101. We also record accruals for estimated ongoing clinical trial costs. Clinical trial costs represent costs incurred by contract research organizations ( CRO Costs incurred in obtaining product or technology licenses are charged immediately to research and development expense if, at acquisition, the product or technology licensed has not no three March 31, 2023.
Compensation Related Costs, Policy [Policy Text Block]	Stock-Based Compensation We recognize compensation cost for all stock-based awards to employees and non-employee consultants based on the grant date fair value of the award. We record stock-based compensation expense over the period during which the employee or other grantee is required to perform services in exchange for the award, which generally represents the scheduled vesting period. We have not
Income Tax, Policy [Policy Text Block]	Income Taxes We account for income taxes using the asset and liability approach promulgated by ASC 740, Income Taxes
Lessee, Leases [Policy Text Block]	Right-of-use Assets and Operating Lease Obligations We account for our leases following the guidance of Accounting Standards Update No. 2016 02, Leases (Topic 842 ASU 2016 02 2016 02 Right-of-use assets not may Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 not Financing leases, formerly referred to as capitalized leases, are treated similarly to operating leases except that the asset subject to the lease is included in the appropriate fixed asset category, rather than recorded as a Right-of-use asset, and depreciated over its estimated useful life, or lease term, if shorter.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk Financial instruments, which potentially subject us to concentrations of credit risk, consist of cash and cash equivalents. Our investment policies limit any such investments to short-term, low-risk instruments. We deposit cash and cash equivalents with financial institutions which are insured to the maximum of federal limitations. Balances in these accounts may
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements We do not not three • Level 1 1 • Level 2 1 not • Level 3 i.e., no 3 A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Where quoted prices are available in an active market, securities are classified as Level 1 not 3 March 31, 2023 2022, 1 March 31, 2023 March 31, 2022.
Warrants Issued In Connection With Equity Financing [Policy Text Block]	Warrants Issued in Connection with Equity Financing We evaluate the appropriate balance sheet classification of warrants we issue as either equity or as a derivative liability. In accordance with ASC 815 40, Derivatives and Hedging-Contracts in the Entity s Own Equity ASC 815 40 not not 480, Distinguishing Liabilities from Equity 815 40, March 31, 2023 2022
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss We have no
Earnings Per Share, Policy [Policy Text Block]	Loss per Common Share Attributable to Common Stockholders Basic net loss attributable to common stockholders per share of common stock excludes the effect of dilution and has historically been computed by dividing net loss increased by the accrual of dividends on outstanding shares of our Series B 10% Convertible Preferred Stock ( Series B Preferred third 2022, As a result of our net loss for both years presented and the conversion of all series of our preferred stock prior to March 31, 2022, March 31, 2023 2022 At March 31, At March 31, 2023 2022 Outstanding options under the Company's Amended and Restated 2016 (formerly 2008) Stock Incentive Plan and 2019 Omnibus Equity Incentive Plan 702,545 646,213 Outstanding warrants to purchase common stock 45,685 309,195 Total 748,230 955,408
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements We believe the following recent accounting pronouncements or changes in accounting pronouncements are of significance or potential significance to the Company. In August 2020, FASB 2020 06, Debt with Conversion and Other Options (Subtopic 470 20 Contracts in Entity s Own Equity 815 40 ASU 2020 06 The guidance in ASU 2020 06 470 20, 470 20 not In addition, the amendments revise the scope exception from derivative accounting in ASC 815 40 not The amendments in ASU 2020 06 260, Earnings Per Share may The amendments in ASU 2020 06 April 1, 2024. not 2020 06 Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not not

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	At March 31, At March 31, 2023 2022 Outstanding options under the Company's Amended and Restated 2016 (formerly 2008) Stock Incentive Plan and 2019 Omnibus Equity Incentive Plan 702,545 646,213 Outstanding warrants to purchase common stock 45,685 309,195 Total 748,230 955,408

Note 4 - Prepaid Expenses and_2

Note 4 - Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	March 31, March 31, 2023 2022 Clinical and nonclinical materials and contract services $ 166,700 $ 2,139,600 Insurance 206,000 196,500 Receivable from CRO for cancelled project - 337,900 Receivable from collaboration partner 274,700 - All other 155,300 71,800 $ 802,700 $ 2,745,800

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment, Net (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, March 31, 2023 2022 Laboratory equipment $ 1,234,800 $ 1,181,300 Tenant improvements 214,400 214,400 Office furniture and equipment 40,300 76,200 Manufacturing equipment 211,200 211,200 1,700,700 1,683,100 Accumulated depreciation and amortization (1,193,400 ) (1,268,800 ) Property and equipment, net $ 507,300 $ 414,300
Schedule of Finance Leased Assets [Table Text Block]	March 31, March 31, 2023 2022 Office equipment subject to financing lease $ 10,600 $ 14,700 Accumulated depreciation (2,000 ) (14,700 ) Net book value of office equipment subject to financing lease $ 8,600 $ -
Depreciation and Amortization, Property, Plant and Equipment [Tabe Text Block]	Fiscal Years Ended March 31, 2023 2022 Owned assets $ 127,500 $ 151,200 Leased assets 2,000 2,300 Total depreciation and amortization $ 129,500 $ 153,500

Note 6 - Accrued Expenses (Tabl

Note 6 - Accrued Expenses (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, March 31, 2023 2022 Accrued expenses for clinical and nonclinical materials, development and contract services $ 412,100 $ 1,070,800 Accrued compensation 337,200 66,200 Accrued professional services 38,100 159,500 All other - 32,700 $ 787,400 $ 1,329,200

Note 7 - Note Payable (Tables)

Note 7 - Note Payable (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Debt [Table Text Block]	March 31, 2023 March 31, 2022 Principal Accrued Principal Accrued Balance Interest Total Balance Interest Total 3.88 $ 105,300 $ - $ 105,300 $ - $ - $ -

Note 8 - Capital Stock (Tables)

Note 8 - Capital Stock (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Assumption: Pre-modification Post-modification Market price per share $ 3.74 $ 3.74 Exercise price per share $ 15.00 $ 15.00 Risk-free interest rate 3.93 % 4.41 % Remaining contractual term in years 0.011 2.012 Volatility 65.60 % 175.27 % Dividend rate 0.0 % 0.0 % Number of warrant shares 33,333 33.333 Weighted average fair value per share $ 0.00 $ 2.40
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Exercise Warrants Outstanding Price Expiration and Exercisable at per Share Date March 31, 2023 $15.00 12/9/2024 33,333 $21.90 7/25/2025 12,352 45,685
Schedule of Stock by Class [Table Text Block]	Pursuant to warrants to purchase common stock: Subject to outstanding warrants 45,685 Pursuant to stock incentive plans: Subject to outstanding options under the Amended and Restated 2016 Stock Incentive Plan and the Amended and Restated 2019 Omnibus Equity Incentive Plan 702,545 Available for future grants under the Amended and Restated 2019 Omnibus Equity Incentive Plan 179,260 Available for future issuance under the 2019 Employee Stock Purchase Plan 24,322 906,127 Reserved for issuance under the Sales Agreement 858,498 Total 1,810,310

Note 10 - Income Taxes (Tables)

Note 10 - Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Fiscal Years Ended March 31, 2023 2022 Computed expected tax benefit (21.00 )% (21.00 )% State income taxes, net of federal benefit 0.00 % 0.01 % Tax effect of warrant modifications 0.03 % 0.00 % Tax effect of research and development credits (0.78 % (0.73 % Tax effect of stock compensation 0.50 % 0.59 % Tax effect of other non-deductible items 1.27 % 0.11 % Expired net operating loss carryforwards 0.17 % 0.74 % Change in valuation allowance (federal only) 18.57 % 20.40 % All other 1.24 % 0.00 % Income tax expense 0.00 % 0.12 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	March 31, 2023 2022 Deferred tax assets: Net operating loss carryovers $ 43,602,800 $ 41,924,800 Basis differences in property and equipment - 47,000 Research and development credit carryforwards 3,591,100 3,032,800 Stock based compensation 2,985,600 3,469,300 Operating lease Right-of-Use asset 73,200 79,700 Capitalized research and development costs 8,214,700 - Deferred revenue 642,500 - Accruals and reserves 146,300 66,700 Total deferred tax assets 59,256,100 48,620,300 Valuation allowance (59,251,300 ) (48,620,300 ) Total deferred tax assets net of valuation allowance 4,800 - Deferred tax liabilities: Basis differences in property and equipment (4,800 ) - Total deferred tax liabilities (4,800 ) - Net deferred tax asset (liability) $ - $ -
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Fiscal Years Ended March 31, 2023 2022 Unrecognized benefit - beginning of period $ 1,088,100 $ 931,900 Current period tax position increases 194,900 156,200 Unrecognized benefit - end of period $ 1,283,000 $ 1,088,100

Note 11 - Licensing, Sublicen_2

Note 11 - Licensing, Sublicensing and Collaborative Agreements (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Revenue Balance at Recognition Balance at March 31, 2021 Amortization Derecognition March 31, 2022 Deferred revenue - current portion $ 1,420,200 $ (176,200 ) $ - $ 1,244,000 Deferred revenue - non-current portion 2,490,300 (932,700 ) - 1,557,600 Total $ 3,910,500 $ (1,108,900 ) $ - $ 2,801,600 Revenue Balance at Recognition Balance at March 31, 2022 Amortization Derecognition March 31, 2023 Deferred revenue - current portion $ 1,244,000 $ (665,300 ) $ 135,600 $ 714,300 Deferred revenue - non-current portion 1,557,600 - 757,000 2,314,600 Total $ 2,801,600 $ (665,300 ) $ 892,600 $ 3,028,900

Note 12 - Stock Option Plans,_2

Note 12 - Stock Option Plans, Employee Stock Purchase Plan, and 401(k) Plan (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Assumption: Pre-modification Post-modification Market price per share $ 6.156 $ 6.156 Exercise price per share $ 38.10 $ 38.10 Risk-free interest rate 2.62 % 3.17 % Remaining contractual term in years 0.003 0.249 Volatility 138.31 % 412.67 % Dividend rate 0.0 % 0.0 % Number of option shares 44,071 44,071 Weighted average fair value per share $ 0.00 $ 2.46 Assumption: Pre-modification Post-modification Market price per share $ 3.57 $ 3.57 Exercise price per share $ 38.10 $ 38.10 Risk-free interest rate 3.86 % 4.38 % Remaining contractual term in years 0.0 0.299 Volatility 92.75 % 99.54 % Dividend rate 0.0 % 0.0 % Number of option shares 44,071 44,071 Weighted average fair value per share $ 0.00 $ 0.002 Fiscal Years Ended March 31, 2023 2022 (weighted average) (weighted average) Exercise price $ 10.20 $ 53.40 Market price on date of grant $ 10.20 $ 53.40 Risk-free interest rate 3.55 % 1.42 % Expected term (years) 6.03 5.60 Volatility 158.03 % 80.27 % Expected dividend yield 0.00 % 0.00 % Fair value per share at grant date $ 8.10 $ 36.00
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Fiscal Years Ended March 31, 2023 2022 Research and development expense $ 1,364,800 $ 1,457,600 General and administrative expense 1,971,600 2,023,100 Total stock-based compensation expense $ 3,336,400 $ 3,480,700
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Fiscal Years Ended March 31, 2023 2022 Weighted Weighted Average Average Number of Exercise Number of Exercise Shares Price Shares Price Options outstanding at beginning of period 646,213 $ 44.10 487,936 $ 40.20 Options granted 143,900 $ 10.20 173,500 $ 53.40 Options exercised (9,533 ) $ 18.30 (11,873 ) $ 24.30 Options forfeited (32,660 ) $ 42.30 (3,333 ) $ 59.70 Options expired (45,374 ) $ 40.80 (17 ) $ 240.00 Options outstanding at end of period 702,545 $ 37.80 646,213 $ 44.10 Options exercisable at end of period 496,257 $ 42.00 452,309 $ 39.60 Weighted average grant-date fair value of options granted during the period $ 8.10 $ 36.00
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Weighted Average Weighted Weighted Remaining Average Average Exercise Number Years until Exercise Number Exercise Price Outstanding Expiration Price Exercisable Price $ 3.57 to $12.30 151,773 8.96 $ 6.47 43,710 $ 11.24 $12.60 to $36.30 128,521 6.06 $ 29.35 117,097 $ 29.41 $38.10 to $41.10 130,833 8.26 $ 40.40 93,042 $ 40.31 $42.30 to $51.00 147,833 4.95 $ 44.74 144,500 $ 44.72 $52.50 to $277.50 143,585 7.89 $ 68.76 97,908 $ 68.34 702,545 7.24 $ 37.76 496,257 $ 41.99

Note 14 - Commitments, Contin_2

Note 14 - Commitments, Contingencies, Guarantees and Indemnifications (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Finance Lease, Assets and Liabilities [Table Text Bock]	March 31, March 31, 2023 2022 Office equipment subject to financing lease $ 10,600 $ 14,700 Accumulated depreciation (2,000 ) (14,700 ) Net book value of office equipment subject to financing lease $ 8,600 $ -
Finance Lease, Liability, to be Paid, Maturity [Table Text Block]	Fiscal Year Ending March 31, 2024 $ 2,900 2025 2,900 2026 2,900 2027 2,900 2028 600 Future minimum lease payments 12,200 Less imputed interest included in minimum lease payments (3,100 ) Present value of minimum lease payments 9,100 Less current portion (1,700 ) Financing lease obligation - non-current portion $ 7,400
Assets and Liabilities, Lessee [Table Text Block]	As of March 31, 2023 As of March 31, 2022 Assets Right-of-use asset – operating lease $ 2,260,300 $ 2,662,000 Liabilities Current operating lease obligation $ 485,600 $ 433,300 Non-current operating lease obligation 2,119,800 2,605,400 Total operating lease liability $ 2,605,400 $ 3,038,700
Lease, Cost [Table Text Block]	For the Fiscal Year Ended For the Fiscal Year Ended March 31, 2023 March 31, 2022 Operating lease cost $ 851,700 $ 725,000
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	Fiscal Years Ending March 31, Amount 2024 $ 689,500 2025 710,200 2026 731,500 2027 753,500 2028 253,600 Total lease expense 3,138,300 Less imputed interest (532,900 ) Present value of operating lease liabilities $ 2,605,400 As of March 31, 2023 Assumed remaining lease term in years 4.33 Assumed discount rate 8.54%
Schedule Of Operating Leaser For Cash Flow Disclosures [Table Text Block]	For the Fiscal Year Ended For the Fiscal Year Ended March 31, 2023 March 31, 2022 Cash paid for amounts included in the measurement of lease liabilities $ 883,200 $ 844,300

Note 16 - Supplemental Financ_2

Note 16 - Supplemental Financial Information (Unaudited) (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Quarterly Financial Information [Table Text Block]	Three Months Ended June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023 Total Fiscal Year 2023 Sublicense revenue $ 310 $ (893 ) $ 180 $ 176 $ (227 ) Total revenue 310 (893 ) 180 176 (227 ) Operating expenses: Research and development 15,291 12,895 6,854 9,337 44,377 General and administrative 4,792 3,702 3,092 3,078 14,664 Total operating expenses 20,083 16,597 9,946 12,415 59,041 Loss from operations (19,773 ) (17,490 ) (9,766 ) (12,239 ) (59,268 ) Other income and expenses, net: Interest income, net 2 6 5 13 26 Loss before income taxes (19,771 ) (17,484 ) (9,761 ) (12,226 ) (59,242 ) Income taxes (5 ) - - (1 ) (6 ) Net loss and comprehensive loss (19,776 ) (17,484 ) (9,761 ) (12,227 ) (59,248 ) Basic and diluted net loss per common share $ (2.87 ) $ (2.54 ) $ (1.42 ) $ (1.71 ) $ (8.51 ) Weighted average shares used in computing basic and diluted net loss per common share 6,886,557 6,893,708 6,894,603 7,163,799 6,958,749 Three Months Ended June 30, 2021 September 30, 2021 December 31, 2021 March 31, 2022 Total Fiscal Year 2022 Sublicense revenue $ 354 $ 358 $ 358 $ 39 $ 1,109 Total revenue 354 358 358 39 1,109 Operating expenses: Research and development 5,458 9,937 7,779 12,234 35,408 General and administrative 2,643 3,221 3,118 4,498 13,480 Total operating expenses 8,101 13,158 10,897 16,732 48,888 Loss from operations (7,747 ) (12,800 ) (10,539 ) (16,693 ) (47,779 ) Other income and expenses, net: Interest income, net 5 5 5 5 20 Loss before income taxes (7,742 ) (12,795 ) (10,534 ) (16,688 ) (47,759 ) Income taxes (3 ) - - - (3 ) Net loss and comprehensive loss (7,745 ) (12,795 ) (10,534 ) (16,688 ) (47,762 ) Accrued dividend on Series B Preferred stock (362 ) (375 ) (208 ) - (945 ) Net loss attributable to common stockholders $ (8,107 ) $ (13,170 ) $ (10,742 ) $ (16,688 ) $ (48,707 ) Basic and diluted net loss per common share attributable to common stockholders $ (1.28 ) $ (2.04 ) $ (1.59 ) $ (2.42 ) $ (7.38 ) Weighted average shares used in computing basic and diluted net loss per common share attributable to common stockholders 6,330,805 6,440,928 6,744,289 6,884,403 6,599,287

Note 1 - Description of Busin_2

Note 1 - Description of Business (Details Textual)		12 Months Ended
	Feb. 02, 2023 USD ($) shares	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022
Statement [Line Items]
Fair Value of Common Stock Issued for Asset Acqusition		$ 3,076,500	$ 0
Payments to Acquire Productive Assets		528,300	0
Expense Related to Asset Acquisition		3,559,400	$ 0
Number of Subsidiaries				2
Pherin Acquisition [Member]
Statement [Line Items]
Asset Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | shares	413,670
Fair Value of Common Stock Issued for Asset Acqusition	$ 3,076,550	$ 3,100,000
Asset Acquisition, Percentage Eligible to Receive Stock Consideration	96.07%
Payments to Acquire Productive Assets	$ 126,100
Asset Acquisition, Percentage of Stockholders Paid in Cash	3.93%
Asset Acquisition, Consideration Transferred, Transaction Cost	$ 402,200
Expense Related to Asset Acquisition	3,559,400
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 45,400

Note 2 - Basis of Presentatio_2

Note 2 - Basis of Presentation and Going Concern (Details Textual)			1 Months Ended	2 Months Ended	12 Months Ended			299 Months Ended
	Jun. 12, 2023 USD ($) shares	Jun. 06, 2023	May 31, 2021 USD ($)	Oct. 31, 2021 USD ($) shares	Mar. 31, 2023 USD ($) shares	Mar. 31, 2022 USD ($) shares	Mar. 31, 2021 USD ($)	Mar. 31, 2023 USD ($)	Jun. 07, 2023 $ / shares
Statement [Line Items]
Retained Earnings (Accumulated Deficit)					$ (326,851,700)	$ (267,604,000)		$ (326,851,700)
Proceeds from Issuance of Debt and Equity Securities								208,700,000
Proceeds from Government Research Grant Awards								22,700,000
Stock Issued During Period, Value, Settlement of Liabilities								41,300,000
Class of Warrant or Right, Warrants, Exercised, Number (in shares) | shares					0	243,293
Proceeds from Warrant Exercises					$ 6,200,000	$ 6,200,000
Proceeds from Sale of Equity Securities, FV-NI							$ 119,000,000
Proceeds from Licensing and Collaboration Agreement							$ 5,000,000
Proceeds from Stock Options Exercised					167,500
Cash and Cash Equivalents, at Carrying Value					16,637,600	68,135,300		$ 16,637,600
ATM Facility [Member]
Statement [Line Items]
Proceeds from Issuance of Common Stock					$ (173,900)	$ 4,299,000
ATM Facility [Member] | Jefferies LLC [Member]
Statement [Line Items]
Stock Sales Agreement, Maximum Aggregate Offering Price			$ 75,000,000
Stock Issued During Period, Shares, New Issues (in shares) | shares				50,593	0
Proceeds from Issuance of Common Stock				$ 4,450,000
Subsequent Event [Member] | Minimum [Member]
Statement [Line Items]
Share Price (in dollars per share) | $ / shares									$ 1
Subsequent Event [Member] | ATM Facility [Member] | Jefferies LLC [Member]
Statement [Line Items]
Stock Issued During Period, Shares, New Issues (in shares) | shares	561,418
Proceeds from Issuance of Common Stock	$ 1,150,000
Reverse Stock Split [Member] | Subsequent Event [Member]
Statement [Line Items]
Stockholders' Equity Note, Stock Split, Conversion Ratio		30

Note 3 - Summary of Significa_3

Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($) shares in Thousands			1 Months Ended			12 Months Ended
	Mar. 31, 2021	Aug. 30, 2020	Nov. 30, 2022	Aug. 31, 2020	Jul. 31, 2014	Mar. 31, 2022	Mar. 31, 2023	Jun. 30, 2021
Series B Preferred Stock [Member]
Statement [Line Items]
Preferred Stock, Dividend Rate, Percentage	10%		10%		10%	10%
Fair Value, Recurring [Member]
Statement [Line Items]
Financial Liabilities Fair Value Disclosure						$ 0	$ 0
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Statement [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure						$ 65,094,900	$ 5,010,800
Restricted Stock [Member]
Statement [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted (in shares)						0
Collaborative Arrangement, AffaMed Agreement [Member] | License [Member]
Statement [Line Items]
Upfront License Payment		$ 5,000,000		$ 5,000,000
Lincoln Park Capital Fund [Member] | Common Stock Purchase Agreement With Lincoln Park Capital Fund [Member]
Statement [Line Items]
Deferred Offering Costs								$ 232,100
Technology Equipment [Member] | Minimum [Member]
Statement [Line Items]
Property, Plant and Equipment, Useful Life (Year)							3 years
Technology Equipment [Member] | Maximum [Member]
Statement [Line Items]
Property, Plant and Equipment, Useful Life (Year)							7 years
Manufacturing Facility [Member] | Minimum [Member]
Statement [Line Items]
Property, Plant and Equipment, Useful Life (Year)							5 years
Manufacturing Facility [Member] | Maximum [Member]
Statement [Line Items]
Property, Plant and Equipment, Useful Life (Year)							10 years

Note 3 - Summary of Significa_4

Note 3 - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded From Earnings Per Share Computation (Details) - shares	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Antidilutive Securities (in shares)	748,230	955,408
Share-Based Payment Arrangement, Option [Member] | The 2019 Omnibus Equity Incentive Plan [Member]
Statement [Line Items]
Antidilutive Securities (in shares)	702,545	646,213
Warrant [Member]
Statement [Line Items]
Antidilutive Securities (in shares)	45,685	309,195

Note 4 - Prepaid Expenses and_3

Note 4 - Prepaid Expenses and Other Current Assets (Details Textual)	12 Months Ended
	Mar. 31, 2023 USD ($)
Statement [Line Items]
Number of Contract Research Organizations	2
Reimbursement from Collaboration Partner	$ 174,700

Note 4 - Prepaid Expenses and_4

Note 4 - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Prepaid Expense and Other Assets, Current	$ 802,700	$ 2,745,800
Prepaid Expenses and Other Current Assets [Member]
Statement [Line Items]
Clinical and nonclinical materials and contract services	166,700	2,139,600
Insurance	206,000	196,500
Receivable from CRO for cancelled project	0	337,900
Receivable from collaboration partner	274,700	0
Other Assets	155,300	71,800
Prepaid Expense and Other Assets, Current	$ 802,700	$ 2,745,800

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment, Net (Details Textual)	9 Months Ended
	Dec. 31, 2022 USD ($)
Lease for Office Equipment Fully-depreciated [Member]
Statement [Line Items]
Lease, Monthly Payment	$ 200

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Property, plant and equipment	$ 1,700,700	$ 1,683,100
Accumulated depreciation and amortization	(1,193,400)	(1,268,800)
Property and equipment, net	507,300	414,300
Laboratory Equipment [Member]
Statement [Line Items]
Property, plant and equipment	1,234,800	1,181,300
Tenant Improvements [Member]
Statement [Line Items]
Property, plant and equipment	214,400	214,400
Office Furniture And Equipment [Member]
Statement [Line Items]
Property, plant and equipment	40,300	76,200
Manufacturing Equipment [Member]
Statement [Line Items]
Property, plant and equipment	$ 211,200	$ 211,200

Note 5 - Property and Equipme_5

Note 5 - Property and Equipment, Net - Schedule of Assets Subject to Financing Lease (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Office equipment subject to financing lease	$ 10,600	$ 14,700
Office Furniture And Equipment [Member]
Statement [Line Items]
Office equipment subject to financing lease	10,600	14,700
Accumulated depreciation	(2,000)	(14,700)
Net book value of office equipment subject to financing lease	$ 8,600	$ 0

Note 5 - Property and Equipme_6

Note 5 - Property and Equipment - Depreciation and Amortization Expense (Details) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Depreciation and amortization	$ 129,500	$ 153,500
Owned Assets [Member]
Statement [Line Items]
Depreciation and amortization	127,500	151,200
Leased Assets [Member]
Statement [Line Items]
Depreciation and amortization	$ 2,000	$ 2,300

Note 6 - Accrued Expenses (Deta

Note 6 - Accrued Expenses (Details Textual) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Employee-related Liabilities, Current, Total	$ 337,200	$ 66,200
Terminated Former Employee [Member]
Statement [Line Items]
Employee-related Liabilities, Current, Total	$ 300,000

Note 6 - Accrued Expenses - Sch

Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Accrued expenses for clinical and nonclinical materials, development and contract services	$ 412,100	$ 1,070,800
Accrued compensation	337,200	66,200
Accrued professional services	38,100	159,500
Other Accrued Liabilities	0	32,700
Accrued Liabilities, Current	$ 787,400	$ 1,329,200

Note 7 - Note Payable (Details

Note 7 - Note Payable (Details Textual) - Promissory Note [Member]	1 Months Ended
	May 31, 2022 USD ($)
Statement [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.88%
Debt Instrument, Face Amount	$ 1,139,700
Debt Instrument, Periodic Payment, Total	$ 105,600

Note 7 - Note Payable - Summary

Note 7 - Note Payable - Summary of Notes Payable (Details) - Promissory Note 3.88% [Member] - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Principal balance	$ 105,300	$ 0
Accrued Interest	0	0
Total balance	$ 105,300	$ 0

Note 7 - Note Payable - Summa_2

Note 7 - Note Payable - Summary of Notes Payable (Details) (Parentheticals)	Mar. 31, 2022
Promissory Note 3.88% [Member]
Statement [Line Items]
Debt Instrument, Interest Rate	3.88%

Note 8 - Capital Stock (Details

Note 8 - Capital Stock (Details Textual) - USD ($)		1 Months Ended								2 Months Ended	3 Months Ended					12 Months Ended
	Mar. 31, 2021	Nov. 30, 2022	Nov. 30, 2021	Oct. 31, 2021	May 31, 2021	Apr. 30, 2021	Mar. 31, 2021	May 31, 2016	Jul. 31, 2014	Oct. 31, 2021	Dec. 31, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2021	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 05, 2022	Mar. 05, 2021	Mar. 04, 2021	Dec. 17, 2020	Jan. 31, 2016	May 31, 2015	Dec. 31, 2011
Statement [Line Items]
Common Stock, Shares Authorized (in shares)													325,000,000			325,000,000		325,000,000		325,000,000	175,000,000
Preferred Stock, Shares Authorized (in shares)													10,000,000			10,000,000		10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)													$ 0.001			$ 0.001		$ 0.001
Preferred Stock, Shares Outstanding, Ending Balance (in shares)													0			0		0
Deferred Offering Costs, Noncurrent													$ 321,800			$ 495,700		$ 321,800
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)																9,533		11,873
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share)																$ 18.30		$ 24.30
Proceeds from Stock Options Exercised																$ 167,500
Stock Issued During Period, Value, Employee Stock Purchase Plan																$ 63,100		$ 99,300
Class of Warrant or Right, Warrants, Exercised, Number (in shares)																0		243,293
Class of Warrant or Right, Expired During Period (in shares)																263,510
Class of Warrant or Right, Expired During Period, Exercise Price (in dollars per share)																$ 48.94
Proceeds from Warrant Exercises																$ 6,200,000		$ 6,200,000
Class of Warrant or Right, Outstanding (in shares)																45,685
Fair Value Adjustment of Warrants																$ 77,400		$ 0
Class of Warrant or Right, Modified [Member]
Statement [Line Items]
Class of Warrant or Right, Outstanding (in shares)																			33,333
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																			$ 15
Class of Warrant or Right, Modified [Member] | General and Administrative Expense [Member]
Statement [Line Items]
Fair Value Adjustment of Warrants											$ 77,400
The Winter 2019 Warrant Modification [Member]
Statement [Line Items]
Class of Warrant or Right, Term (Year)																		2 years
The 2019 Employee Stock Purchase Plan [Member]
Statement [Line Items]
Class of Warrant or Right, Weighted Average Exercise Price (in dollars per share)																$ 16.87
Common Stock, Shares, Issuable (in shares)																315,878,808
Amended 2019 Plan [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)																9,533		11,873
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share)																$ 18.30
Proceeds from Stock Options Exercised																$ 104,400		$ 140,000
Stock Issued During Period Shares Stock Options Exercised, Net (in shares)																10,223		7,346
Class of Warrant or Right, Weighted Average Exercise Price (in dollars per share)																		$ 24.30
The 2019 Employee Stock Purchase Plan [Member]
Statement [Line Items]
Stock Issued During Period Shares Stock Options Exercised, Net (in shares)												2,500					2,667
Stock Issued During Period, Value, Employee Stock Purchase Plan											$ 7,000	$ 56,100		$ 67,800	$ 31,600
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)														1,365	542
ATM Facility [Member]
Statement [Line Items]
Proceeds from Issuance of Common Stock																$ (173,900)		$ 4,299,000
ATM Facility [Member] | Jefferies LLC [Member]
Statement [Line Items]
Stock Sales Agreement, Maximum Aggregate Offering Price					$ 75,000,000
Stock Sales Agreement, Commission on Shares Sold, Percentage					3%
Stock Issued During Period, Shares, New Issues (in shares)										50,593						0
Proceeds from Issuance of Common Stock										$ 4,450,000
Deferred Offering Costs, Noncurrent																$ 450,300
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs																$ 0		$ 16,400
Conversion of Series A Preferred into Common Stock [Member]
Statement [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)																									0.05
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	500,000						500,000
Preferred Stock, Convertible, Shares Issuable (in shares)	25,000						25,000
Conversion of Stock, Shares Converted (in shares)			500,000
Conversion of Stock, Shares Issued (in shares)			25,000
Conversion of Series B Preferred Stock Into Common Stock [Member]
Statement [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)								0.033
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	1,131,669		1,131,669				1,131,669
Preferred Stock, Convertible, Shares Issuable (in shares)	37,722		37,722				37,722
Conversion of Stock, Shares Converted (in shares)								2,400,000
Conversion of Stock, Shares Issued (in shares)								80,000
Conversion of Series B Preferred Stock Into Registered Common Stock [Member]
Statement [Line Items]
Conversion of Stock, Shares Issued (in shares)			13,151
Conversion of Series B Preferred Stock Into Unregistered Common Stock [Member]
Statement [Line Items]
Conversion of Stock, Shares Issued (in shares)			24,571
Conversion of Accrued Dividends on Series B Preferred Stock into Common Stock [Member]
Statement [Line Items]
Conversion of Stock, Shares Issued (in shares)			109,860
Conversion of Stock, Amount Converted			$ 7,217,800
Conversion of Series C Preferred Stock to Common Stock [Member]
Statement [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)																							1
Conversion of Stock, Shares Converted (in shares)				2,318,012
Conversion of Stock, Shares Issued (in shares)				77,267
Conversion of Series D Preferred Stock Into Common Stock [Member]
Statement [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)																						0.7667
Conversion of Stock, Shares Converted (in shares)							1,597,851
Conversion of Stock, Shares Issued (in shares)							1,225,019
Series A Preferred Stock [Member]
Statement [Line Items]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)																									$ 0.001
Series A Preferred Stock [Member] | Maximum [Member]
Statement [Line Items]
Preferred Stock, Shares Authorized (in shares)																									500,000
Series B Preferred Stock [Member]
Statement [Line Items]
Preferred Stock, Shares Authorized (in shares)																								4,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)									$ 0.001
Preferred Stock, Dividend Rate, Percentage	10%	10%							10%									10%
Dividends, Preferred Stock		$ 945,100
Series C Preferred Stock [Member]
Statement [Line Items]
Preferred Stock, Shares Authorized (in shares)																							3,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)																							$ 0.001
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	2,318,012						2,318,012
Series D Preferred Stock [Member]
Statement [Line Items]
Preferred Stock, Shares Authorized (in shares)																						2,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)																						$ 0.001
Series D Preferred Stock [Member] | The 2020 December Public Offering [Member]
Statement [Line Items]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	402,149						402,149						0			0		0
Conversion of Stock, Shares Converted (in shares)						402,149
Conversion of Stock, Shares Issued (in shares)						308,314							308,314

Note 8 - Capital Stock - Assump

Note 8 - Capital Stock - Assumptions of Warrant Modification (Details)	Mar. 31, 2023 shares	Dec. 05, 2022 $ / shares shares
Statement [Line Items]
Class of Warrant or Right, Outstanding (in shares)	45,685
Pre-modification Warrants [Member]
Statement [Line Items]
Class of Warrant or Right, Outstanding (in shares)		33,333
Weighted average fair value per share (in dollars per share) | $ / shares		$ 0
Pre-modification Warrants [Member] | Measurement Input, Share Price [Member]
Statement [Line Items]
Assumption		3.74
Pre-modification Warrants [Member] | Measurement Input, Exercise Price [Member]
Statement [Line Items]
Assumption		15
Pre-modification Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Statement [Line Items]
Assumption		3.93
Pre-modification Warrants [Member] | Measurement Input, Expected Term [Member]
Statement [Line Items]
Assumption		0.011
Pre-modification Warrants [Member] | Measurement Input, Price Volatility [Member]
Statement [Line Items]
Assumption		65.60
Pre-modification Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Statement [Line Items]
Assumption		0
Post-modification Warrants [Member]
Statement [Line Items]
Class of Warrant or Right, Outstanding (in shares)		33.333
Weighted average fair value per share (in dollars per share) | $ / shares		$ 2.40
Post-modification Warrants [Member] | Measurement Input, Share Price [Member]
Statement [Line Items]
Assumption		3.74
Post-modification Warrants [Member] | Measurement Input, Exercise Price [Member]
Statement [Line Items]
Assumption		15
Post-modification Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Statement [Line Items]
Assumption		4.41
Post-modification Warrants [Member] | Measurement Input, Expected Term [Member]
Statement [Line Items]
Assumption		2.012
Post-modification Warrants [Member] | Measurement Input, Price Volatility [Member]
Statement [Line Items]
Assumption		175.27
Post-modification Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Statement [Line Items]
Assumption		0

Note 8 - Capital Stock - Schedu

Note 8 - Capital Stock - Schedule of Warrants (Details)	Mar. 31, 2023 $ / shares shares
Statement [Line Items]
Class of Warrant or Right, Outstanding (in shares)	45,685
Warrants Expiring December 9, 2024 [Member]
Statement [Line Items]
Class of Warrant or Right, Exercise Price (in dollars per share) | $ / shares
Class of Warrant or Right, Outstanding (in shares)	33,333
Warrants Expiring July 25, 2025 [Member]
Statement [Line Items]
Class of Warrant or Right, Exercise Price (in dollars per share) | $ / shares
Class of Warrant or Right, Outstanding (in shares)	12,352

Note 8 - Capital Stock - Reserv

Note 8 - Capital Stock - Reserves Shares (Details)	Mar. 31, 2023 shares
Statement [Line Items]
Reserved for future issuance (in shares)	1,810,310
The 2016 Equity Incentive Plan [Member]
Statement [Line Items]
Reserved for future issuance (in shares)	702,545
Amended 2019 Plan [Member]
Statement [Line Items]
Reserved for future issuance (in shares)	179,260
Employee Stock Purchase Plan 2019 [Member]
Statement [Line Items]
Reserved for future issuance (in shares)	24,322
Stock Incentive Plans [Member]
Statement [Line Items]
Reserved for future issuance (in shares)	906,127
Open Market Sale Agreement [Member]
Statement [Line Items]
Reserved for future issuance (in shares)	858,498
Warrant [Member]
Statement [Line Items]
Reserved for future issuance (in shares)	45,685

Note 9 - Research and Develop_2

Note 9 - Research and Development Expenses (Details Textual) - USD ($)		3 Months Ended								12 Months Ended
	Feb. 02, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Research and Development Expense		$ 9,337,000	$ 6,854,000	$ 12,895,000	$ 15,291,000	$ 12,234,000	$ 7,779,000	$ 9,937,000	$ 5,458,000	$ 44,377,100	$ 35,407,800
Research and Development Expense, Noncash										4,600,000	1,500,000
Fair Value of Common Stock Issued for Asset Acqusition										3,076,500	$ 0
Pherin Acquisition [Member]
Statement [Line Items]
Fair Value of Common Stock Issued for Asset Acqusition	$ 3,076,550									$ 3,100,000

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21%	21%
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	$ 10,631,000	$ 8,743,700
Deferred Tax Assets, Taxable Income Limitation	80%
Capitalized Research and Development Costs	$ 42,755,300
Unrecognized Tax Benefits	1,283,000	1,088,100	$ 931,900
Research Tax Credit Carryforward [Member]
Statement [Line Items]
Unrecognized Tax Benefits	1,283,000	$ 1,088,100
Domestic Tax Authority [Member]
Statement [Line Items]
Operating Loss Carryforwards	191,935,600
Operating Loss Carryforwards, Subject to Expiration	84,111,700
Operating Loss Carryforwards, Not Subject to Expiration	107,823,900
Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]
Statement [Line Items]
Tax Credit Carryforward, Amount	3,495,500
State and Local Jurisdiction [Member]
Statement [Line Items]
Operating Loss Carryforwards, Subject to Expiration	65,195,200
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]
Statement [Line Items]
Tax Credit Carryforward, Amount	$ 1,636,200

Note 10 - Income Taxes - Income

Note 10 - Income Taxes - Income Tax Expense (Benefit) (Details)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Computed expected tax benefit	(21.00%)	(21.00%)
State income taxes, net of federal benefit	0%	0.01%
Tax effect of warrant modifications	0.03%	0%
Tax effect of research and development credits	(0.78%)	(0.73%)
Tax effect of stock compensation	0.50%	0.59%
Tax effect of other non-deductible items	1.27%	0.11%
Expired net operating loss carryforwards	0.17%	0.74%
Change in valuation allowance (federal only)	18.57%	20.40%
All other	1.24%	0%
Income tax expense	0%	0.12%

Note 10 - Income Taxes - Deferr

Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Net operating loss carryovers	$ 43,602,800	$ 41,924,800
Basis differences in property and equipment	0	47,000
Research and development credit carryforwards	3,591,100	3,032,800
Stock based compensation	2,985,600	3,469,300
Operating lease Right-of-Use asset	73,200	79,700
Capitalized research and development costs	8,214,700	0
Deferred revenue	642,500	0
Accruals and reserves	146,300	66,700
Total deferred tax assets	59,256,100	48,620,300
Valuation allowance	(59,251,300)	(48,620,300)
Total deferred tax assets net of valuation allowance	4,800	0
Basis differences in property and equipment	(4,800)	0
Total deferred tax liabilities	(4,800)	0
Net deferred tax asset (liability)	$ 0	$ 0

Note 10 - Income Taxes - Uncert

Note 10 - Income Taxes - Uncertain Tax Positions (Details) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Unrecognized benefit - beginning of period	$ 1,088,100	$ 931,900
Current period tax position increases	194,900	156,200
Unrecognized benefit - end of period	$ 1,283,000	$ 1,088,100

Note 11 - Licensing, Sublicen_3

Note 11 - Licensing, Sublicensing and Collaborative Agreements (Details Textual) - USD ($)		1 Months Ended			3 Months Ended		12 Months Ended
	Aug. 30, 2020	Aug. 31, 2020	Oct. 31, 2018	Sep. 30, 2018	Sep. 30, 2022	Sep. 30, 2020	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Revenue from Contract with Customer Including Assessed Tax, Derecognized							$ 227,300
Stock Issued During Period, Value, New Issues								$ 4,299,100
Collaborative Arrangement, AffaMed Agreement [Member]
Statement [Line Items]
Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress							1,971,100	1,108,900
Sublicense Fees						$ 345,000
Stock Issued During Period, Value, Issued for Services						125,000
Capitalized Contract Cost, Gross						470,000
Capitalized Contract Cost, Amortization							21,400	104,100
Capitalized Contract Cost, Impairment Loss							0	$ 0
Stock Issued During Period, Shares, New Issues (in shares)				54,348
Stock Issued During Period, Value, New Issues				$ 2,250,000
Collaborative Arrangement, AffaMed Agreement [Member] | Corporate Development and Public Relations Advisory Services [Member]
Statement [Line Items]
Related Party Transaction, Reversed Expenses from Transactions with Related Party						$ 83,900
Collaborative Arrangement, AffaMed Agreement [Member] | License [Member]
Statement [Line Items]
Upfront License Payment	$ 5,000,000	$ 5,000,000
Revenue Recognition, Milestone Method, Maximum Milestone Payments Permitted		$ 172,000,000
Revenue from Contract with Customer Including Assessed Tax, Derecognized					$ 892,600		227,300
Contract with Customer, Liability							$ 3,028,900
Collaborative Arrangement, License Agreements With Pherin Pharmaceuticals, Inc [Member]
Statement [Line Items]
Stock Issued During Period, Shares, New Issues (in shares)			30,864
Stock Issued During Period, Value, New Issues			$ 2,000,000

Note 11 - Licensing, Sublicen_4

Note 11 - Licensing, Sublicensing and Collaborative Agreements - Changes in Contract Liabilities (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Deferred revenue - current portion	$ 714,300	$ 1,244,000	$ 1,420,200
Deferred revenue - non-current portion	2,314,600	1,557,600	2,490,300
Total	3,028,900	2,801,600	$ 3,910,500
Additions [Member]
Statement [Line Items]
Deferred revenue - current portion	(665,300)	(176,200)
Deferred revenue - non-current portion	0	(932,700)
Total	(665,300)	(1,108,900)
Deductions [Member]
Statement [Line Items]
Deferred revenue - current portion	135,600	0
Deferred revenue - non-current portion	757,000	0
Total	$ 892,600	$ 0

Note 12 - Stock Option Plans,_3

Note 12 - Stock Option Plans, Employee Stock Purchase Plan, and 401(k) Plan (Details Textual) - USD ($)			1 Months Ended	3 Months Ended								12 Months Ended
	Dec. 12, 2022	Sep. 12, 2022	Nov. 30, 2022	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)				702,545				646,213				702,545	646,213	487,936
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)												143,900	173,500
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)												$ 8.10	$ 36
Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable (in shares)		44,071
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)		$ 11.94
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)		$ 53.10
Research and Development Expense				$ 9,337,000	$ 6,854,000	$ 12,895,000	$ 15,291,000	$ 12,234,000	$ 7,779,000	$ 9,937,000	$ 5,458,000	$ 44,377,100	$ 35,407,800
General and Administrative Expense				$ 3,078,000	$ 3,092,000	$ 3,702,000	$ 4,792,000	4,498,000	$ 3,118,000	$ 3,221,000	$ 2,643,000	$ 14,663,600	13,480,000
Dividends, Total													$ 0
Share-Based Payment Arrangement, Option [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)												$ 8.10	$ 36
Research and Development Expense	$ 100	$ 108,600										$ 108,700
The 2016 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)				333,333								333,333
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)				215,773								215,773
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized, Transferred (in shares)				46,280								46,280
Amended 2019 Plan [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)				33,333								33,333
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)				179,260								179,260
Share Price (in dollars per share)				$ 3.74								$ 3.74
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value				$ 4,800								$ 4,800
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount				$ 3,775,500								$ 3,775,500
Amended 2019 Plan [Member] | Share-Based Payment Arrangement, Employee [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			96,667
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)			$ 4.4370
Amended 2019 Plan [Member] | Newly Hired Employee [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)												33,900
Amended 2019 Plan [Member] | Maximum [Member] | Newly Hired Employee [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)												$ 45.30
Amended 2019 Plan [Member] | Minimum [Member] | Newly Hired Employee [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)												$ 3.57
Amended 2019 Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)				600,000								600,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)												143,900
Amended 2019 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Employee [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)													81,333
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)			3 years										2 years
Amended 2019 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Newly Hired Employee [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)													55,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)													3 years
Amended 2019 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Consultants [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)													13,000
Amended 2019 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Officers and Employees [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)													136,333
Amended 2019 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Independent Members of the Board [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)													24,167
Amended 2019 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | New Independent Members of the Board [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)													7,500
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)													1 year
Amended 2019 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche One [Member] | Share-Based Payment Arrangement, Employee [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage			25%										25%
Amended 2019 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche One [Member] | Newly Hired Employee [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage												25%	25%
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)												3 years
Amended 2019 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche One [Member] | Consultants [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)												13,333
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage												25%	25%
Amended 2019 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member] | Consultants [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)													2 years
Amended 2019 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage													25%
Amended 2019 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member] | Consultants [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)													1 year
Amended 2019 Plan [Member] | Performance Shares [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)													0
Plan 2019 [Member] | Share-Based Payment Arrangement, Option [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)				250,000								250,000
The 2019 Omnibus Equity Incentive Plan [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)													173,500
Employee Stock Purchase Plan 2019 [Member]
Statement [Line Items]
Research and Development Expense												$ 37,000	$ 47,000
General and Administrative Expense												14,500	19,500
Accrued Payroll Taxes				$ 17,400				$ 66,200				$ 17,400	$ 66,200
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award (in shares)												5,167	1,907
Proceeds from Issuance of Common Stock												$ 63,100	$ 99,500
Employee Stock Purchase Plan 2019 [Member] | Maximum [Member]
Statement [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Limitation on Contribution of Compensation								15%					15%
Employee Stock Purchase Plan 2019 [Member] | Minimum [Member]
Statement [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Limitation on Contribution of Compensation								1%					1%

Note 12 - Stock Option Plans,_4

Note 12 - Stock Option Plans, Employee Stock Purchase Plan, and 401(k) Plan - Schedule of Fair Value of Options Granted - Black-Scholes Option Pricing Model (Details) - $ / shares			12 Months Ended
	Dec. 12, 2022	Sep. 12, 2022	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Weighted average fair value per share (in dollars per share)			$ 8.10	$ 36
Pre-modified Stock Option Plan [Member]
Statement [Line Items]
Market price per share (in dollars per share)	$ 3.57	$ 6.156
Exercise price per share (in dollars per share)	$ 38.10	$ 38.10
Risk-free interest rate	3.86%	2.62%
Remaining contractual term in years (Year)	0 years	1 day
Volatility	92.75%	138.31%
Dividend rate	0%	0%
Number of option shares (in shares)	44,071	44,071
Weighted average fair value per share (in dollars per share)	$ 0	$ 0
Share-Based Payment Arrangement, Option [Member]
Statement [Line Items]
Exercise price per share (in dollars per share)			$ 10.20	$ 53.40
Risk-free interest rate			3.55%	1.42%
Remaining contractual term in years (Year)			6 years 10 days	5 years 7 months 6 days
Dividend rate			0%	0%
Weighted average fair value per share (in dollars per share)			$ 8.10	$ 36
Market price on date of grant (in dollars per share)			$ 10.20	$ 53.40
Volatility			158.03%	80.27%
Post-modified Stock Option Plan [Member]
Statement [Line Items]
Market price per share (in dollars per share)	3.57	6.156
Exercise price per share (in dollars per share)	$ 38.10	$ 38.10
Risk-free interest rate	4.38%	3.17%
Remaining contractual term in years (Year)	3 months 17 days	2 months 30 days
Volatility	99.54%	412.67%
Dividend rate	0%	0%
Number of option shares (in shares)	44,071	44,071
Weighted average fair value per share (in dollars per share)	$ 0.002	$ 2.46

Note 12 - Stock Option Plans,_5

Note 12 - Stock Option Plans, Employee Stock Purchase Plan, and 401(k) Plan - Consolidated Statement of Operations and Comprehensive Loss (Details) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Stock-based compensation expense	$ 3,336,400	$ 3,480,700
Research and Development Expense [Member]
Statement [Line Items]
Stock-based compensation expense	1,364,800	1,457,600
General and Administrative Expense [Member]
Statement [Line Items]
Stock-based compensation expense	$ 1,971,600	$ 2,023,100

Note 12 - Stock Option Plans,_6

Note 12 - Stock Option Plans, Employee Stock Purchase Plan, and 401(k) Plan - Summary of Stock Option Activity (Details) - $ / shares	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Options outstanding at beginning of period (in shares)	646,213	487,936
Options outstan, weighted average exercise price (in dollars per share)	$ 44.10	$ 40.20
Options granted (in shares)	143,900	173,500
Options granted, weighted average exercise price (in dollars per share)	$ 10.20	$ 53.40
Options exercised (in shares)	(9,533)	(11,873)
Options exercised, weighted average exercise price (in dollars per share)	$ 18.30	$ 24.30
Options forfeited (in shares)	(32,660)	(3,333)
Options forfeited, weighted average exercise price (in dollars per share)	$ 42.30	$ 59.70
Options expired (in shares)	(45,374)	(17)
Options expired, weighted average exercise price (in dollars per share)	$ 40.80	$ 240
Options outstanding at end of period (in shares)	702,545	646,213
Options outstan, weighted average exercise price (in dollars per share)	$ 37.80	$ 44.10
Options exercisable at end of period (in shares)	496,257	452,309
Options exercisable, weighted average exercise price (in dollars per share)	$ 42	$ 39.60
Weighted average fair value per share (in dollars per share)	$ 8.10	$ 36

Note 12 - Stock Option Plans,_7

Note 12 - Stock Option Plans, Employee Stock Purchase Plan, and 401(k) Plan - Stock Option Outstanding and Exercisable (Details) - $ / shares		12 Months Ended
	Sep. 12, 2022	Mar. 31, 2023
Statement [Line Items]
Exercise price, lower limit (in dollars per share)	$ 11.94
Exercise price, upper limit (in dollars per share)	$ 53.10
Number exercisable shares (in shares)	44,071
Exercise Price Range 1 [Member]
Statement [Line Items]
Exercise price, lower limit (in dollars per share)		$ 3.57
Exercise price, upper limit (in dollars per share)		$ 12.30
Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding, Ending Balance (in shares)		151,773
Weighted average remaining years until expiration (Year)		8 years 11 months 15 days
Weighted average exercise price (in dollars per share)		$ 6.47
Number exercisable shares (in shares)		43,710
Exercisable weighted average exercise price (in dollars per share)		$ 11.24
Exercise Price Range 2 [Member]
Statement [Line Items]
Exercise price, lower limit (in dollars per share)		12.60
Exercise price, upper limit (in dollars per share)		$ 36.30
Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding, Ending Balance (in shares)		128,521
Weighted average remaining years until expiration (Year)		6 years 21 days
Weighted average exercise price (in dollars per share)		$ 29.35
Number exercisable shares (in shares)		117,097
Exercisable weighted average exercise price (in dollars per share)		$ 29.41
Exercise Price Range 3 [Member]
Statement [Line Items]
Exercise price, lower limit (in dollars per share)		38.10
Exercise price, upper limit (in dollars per share)		$ 41.10
Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding, Ending Balance (in shares)		130,833
Weighted average remaining years until expiration (Year)		8 years 3 months 3 days
Weighted average exercise price (in dollars per share)		$ 40.40
Number exercisable shares (in shares)		93,042
Exercisable weighted average exercise price (in dollars per share)		$ 40.31
Exercise Price Range 4 [Member]
Statement [Line Items]
Exercise price, lower limit (in dollars per share)		42.30
Exercise price, upper limit (in dollars per share)		$ 51
Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding, Ending Balance (in shares)		147,833
Weighted average remaining years until expiration (Year)		4 years 11 months 12 days
Weighted average exercise price (in dollars per share)		$ 44.74
Number exercisable shares (in shares)		144,500
Exercisable weighted average exercise price (in dollars per share)		$ 44.72
Exercise Price Range 5 [Member]
Statement [Line Items]
Exercise price, lower limit (in dollars per share)		52.50
Exercise price, upper limit (in dollars per share)		$ 277.50
Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding, Ending Balance (in shares)		143,585
Weighted average remaining years until expiration (Year)		7 years 10 months 20 days
Weighted average exercise price (in dollars per share)		$ 68.76
Number exercisable shares (in shares)		97,908
Exercisable weighted average exercise price (in dollars per share)		$ 68.34
Exercise Price Range 6 [Member]
Statement [Line Items]
Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding, Ending Balance (in shares)		702,545
Weighted average remaining years until expiration (Year)		7 years 2 months 26 days
Weighted average exercise price (in dollars per share)		$ 37.76
Number exercisable shares (in shares)		496,257
Exercisable weighted average exercise price (in dollars per share)		$ 41.99

Note 13 - Related Party Trans_2

Note 13 - Related Party Transactions (Details Textual) - USD ($)	2 Months Ended	3 Months Ended								12 Months Ended		24 Months Ended
	Dec. 31, 2022	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Dec. 01, 2022	Nov. 11, 2022
Statement [Line Items]
General and Administrative Expense		$ 3,078,000	$ 3,092,000	$ 3,702,000	$ 4,792,000	$ 4,498,000	$ 3,118,000	$ 3,221,000	$ 2,643,000	$ 14,663,600	$ 13,480,000
Accrued Liabilities, Current		787,400				1,329,200				787,400	1,329,200	$ 787,400
Research and Development Expense		9,337,000	6,854,000	$ 12,895,000	$ 15,291,000	12,234,000	7,779,000	$ 9,937,000	$ 5,458,000	44,377,100	$ 35,407,800
Consulting Firm [Member] | Corporate Development and Public Relations Advisory Services [Member] | Related Party [Member]
Statement [Line Items]
Operating Costs and Expenses						$ 45,000
General and Administrative Expense												165,000
Accrued Liabilities, Current		10,000								10,000		10,000
i3 Strategy Partners [Member] | Advisory Services [Member]
Statement [Line Items]
Related Party Transaction, Amounts of Transaction	$ 120,000
Related Party Transaction, Monthly Fee														$ 10,000
Dr. Mark Smith [Member] | Consulting Services [Member]
Statement [Line Items]
Related Party Transaction, Monthly Fee													$ 10,000
Dr. Mark Smith [Member] | Consulting Services [Member] | Related Party [Member]
Statement [Line Items]
Operating Costs and Expenses			$ 50,000
Dr. Mark Smith [Member] | Projects for Certain CNS Pipeline Candidates [Member]
Statement [Line Items]
Research and Development Expense										80,000
Accounts Payable and Accrued Liabilities, Current		$ 10,000								$ 10,000		$ 10,000
Joanne Curley [Member] | Consulting Services [Member] | Related Party [Member]
Statement [Line Items]
Research and Development Expense							6,800
Accounts Payable							$ 1,800

Note 14 - Commitments, Contin_3

Note 14 - Commitments, Contingencies, Guarantees and Indemnifications (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Operating Lease, Expense	$ 14,200	$ 14,200

Note 14 - Commitments, Contin_4

Note 14 - Commitments, Contingencies, Guarantees and Indemnifications - Finance Lease Obligations (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Office equipment subject to financing lease	$ 10,600	$ 14,700
Property and Equipment, Net [Member]
Statement [Line Items]
Net book value of office equipment subject to financing lease	8,600	0
Office Equipment [Member]
Statement [Line Items]
Accumulated depreciation	$ (2,000)	$ (14,700)

Note 14 - Commitments and Conti

Note 14 - Commitments and Contingencies - Schedule of Financing Lease Minimum Payments (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
2024	$ 2,900
2025	2,900
2026	2,900
2027	2,900
2028	600
Future minimum lease payments	12,200
Less imputed interest included in minimum lease payments	(3,100)
Present value of minimum lease payments	9,100
Less current portion	(1,700)	$ 0
Financing lease obligation - non-current portion	$ 7,400	$ 0

Note 14 - Commitments, Contin_5

Note 14 - Commitments, Contingencies, Guarantees and Indemnifications - Operating lease in Condensed Consolidated Balance Sheet (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Right-of-use asset – operating lease	$ 2,260,300	$ 2,662,000
Current operating lease obligation	485,600	433,300
Non-current operating lease obligation	2,119,800	2,605,400
Total operating lease liability	$ 2,605,400	$ 3,038,700

Note 14 - Commitments, Contin_6

Note 14 - Commitments, Contingencies, Guarantees and Indemnifications - Operating Lease Cost (Details) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Operating lease cost	$ 851,700	$ 725,000

Note 14 - Commitments, Contin_7

Note 14 - Commitments, Contingencies, Guarantees and Indemnifications - Minimum Lease Payments (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
2024	$ 689,500
2025	710,200
2026	731,500
2027	753,500
2028	253,600
Total lease expense	3,138,300
Less imputed interest	(532,900)
Present value of operating lease liabilities	$ 2,605,400	$ 3,038,700
Assumed remaining lease term in years (Year)	4 years 3 months 29 days
Assumed discount rate	8.54%

Note 14 - Commitments, Contin_8

Note 14 - Commitments, Contingencies, Guarantees and Indemnifications - Operating Activities in Cash flow Statements (Details) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Cash paid for amounts included in the measurement of lease liabilities	$ 883,200	$ 844,300

Note 15 - Subsequent Events (De

Note 15 - Subsequent Events (Details Textual)		1 Months Ended	12 Months Ended
	Jun. 06, 2023 $ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares	Mar. 31, 2023 $ / shares shares	Mar. 31, 2022 $ / shares shares	Mar. 05, 2021 shares	Mar. 04, 2021 shares
Statement [Line Items]
Common Stock, Shares Authorized (in shares)			325,000,000	325,000,000	325,000,000	175,000,000
Preferred Stock, Shares Authorized (in shares)			10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares			$ 0.001	$ 0.001
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			143,900	173,500
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares			$ 0.001	$ 0.001
Subsequent Event [Member]
Statement [Line Items]
Common Stock, Shares Authorized (in shares)	325,000,000
Preferred Stock, Shares Authorized (in shares)	10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.001
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.001
Subsequent Event [Member] | Plan 2019 [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)		10,000
Subsequent Event [Member] | Plan 2019 [Member] | Share-Based Payment Arrangement, Option [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)		5 years
Subsequent Event [Member] | Plan 2019 [Member] | Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage		25%
Subsequent Event [Member] | Plan 2019 [Member] | Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Statement [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage		75%
Subsequent Event [Member] | Sales Agreement [Member]
Statement [Line Items]
Stock Issued During Period, Shares, New Issues (in shares)		561,418
Shares Issued, Price Per Share (in dollars per share) | $ / shares		$ 2.05
Proceeds from Issuance of Common Stock | $		$ 1,151,884
Reverse Stock Split [Member] | Subsequent Event [Member]
Statement [Line Items]
Stockholders' Equity Note, Stock Split, Conversion Ratio	30

Note 16 - Supplemental Financ_3

Note 16 - Supplemental Financial Information (Unaudited) - Quarterly Results of Operations (Unaudited) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Sublicense revenue										$ 1,108,900
Total revenue	$ 176,000	$ 180,000	$ (893,000)	$ 310,000	$ 39,000	$ 358,000	$ 358,000	$ 354,000	$ (227,000)	1,109,000
Research and development	9,337,000	6,854,000	12,895,000	15,291,000	12,234,000	7,779,000	9,937,000	5,458,000	44,377,100	35,407,800
General and administrative	3,078,000	3,092,000	3,702,000	4,792,000	4,498,000	3,118,000	3,221,000	2,643,000	14,663,600	13,480,000
Total operating expenses	12,415,000	9,946,000	16,597,000	20,083,000	16,732,000	10,897,000	13,158,000	8,101,000	59,040,700	48,887,800
Loss from operations	(12,239,000)	(9,766,000)	(17,490,000)	(19,773,000)	(16,693,000)	(10,539,000)	(12,800,000)	(7,747,000)	(59,268,000)	(47,778,900)
Interest income, net	13,000	5,000	6,000	2,000	5,000	5,000	5,000	5,000	26,200	19,900
Loss before income taxes	(12,226,000)	(9,761,000)	(17,484,000)	(19,771,000)	(16,688,000)	(10,534,000)	(12,795,000)	(7,742,000)	(59,241,800)	(47,759,000)
Income taxes	(1,000)	0	0	(5,000)	0	0	0	(3,000)	(5,900)	(3,400)
Net loss and comprehensive loss	$ (12,227,000)	$ (9,761,000)	$ (17,484,000)	$ (19,776,000)	$ (16,688,000)	$ (10,534,000)	$ (12,795,000)	$ (7,745,000)	$ (59,247,700)	$ (47,762,400)
Basic and diluted net loss per common share (in dollars per share)	$ (1.71)	$ (1.42)	$ (2.54)	$ (2.87)	$ (2.42)	$ (1.59)	$ (2.04)	$ (1.28)	$ (8.51)	$ (7.38)
Weighted average shares used in computing basic and diluted net loss per common share (in shares)	7,163,799	6,894,603	6,893,708	6,886,557	6,884,403	6,744,289	6,440,928	6,330,805	6,958,749	6,599,287
Accrued dividend on Series B Preferred stock					$ 0	$ (208,000)	$ (375,000)	$ (362,000)	$ 0	$ (945,100)
Net loss attributable to common stockholders					(16,688,000)	(10,742,000)	(13,170,000)	(8,107,000)	(59,247,700)	(48,707,500)
License [Member]
Statement [Line Items]
Sublicense revenue	$ 176,000	$ 180,000	$ (893,000)	$ 310,000	$ 39,000	$ 358,000	$ 358,000	$ 354,000	$ (227,000)	$ 1,109,000